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ABSTRACT

Chronic lymphocytic leukemia (CLL) is the most common leukemia in developed
countries. It is characterized by the accumulation of CD5+ B lymphocytes in the peripheral blood,
bone marrow, and lymphoid tissues of affected patients. Patients experience lymphadenopathy,
fatigue, and are severely immunocompromised. Management of disease and symptoms is
possible with chemo-immunotherapy for higher risk patients; however, CLL remains incurable
unless bone marrow transplant is performed. Identification of novel targets and optimization of
current therapeutics is therefore still necessary. The new targeted therapies are at the forefront
of development for CLL treatment, but it remains challenging to maximize their efficacies while
avoiding toxicities.
In this body of work, experimental results demonstrated a role for epigenetic modifier
histone deacetylase 6 (HDAC6) in CLL B-cell biology and suggest that targeting of HDAC6 is an
effective, novel strategy against chronic lymphocytic leukemia. Antitumor effects occurred through
blockade of intrinsic survival signaling and through beneficial immunomodulation. Briefly, this data
showed that genetic silencing or pharmacological inhibition of HDAC6 in preclinical CLL mouse
models reduced tumor burden and increased survival through inhibition of pro-survival, antiapoptotic B-cell receptor signaling in CLL B cells. Further interrogation of B-cell receptor signaling
was performed ex vivo, showing transcriptional downregulation of spleen tyrosine kinase (SYK)
and reduced protein expression of anti-apoptotic transcription factors myeloid cell leukemia
(MCL)-1 and B cell lymphoma (BCL)-2.
Based on the ability of HDAC6 to alter intrinsic survival signaling, a rational combinatorial
treatment with ibrutinib, a frontline CLL therapeutic, was tested. The combination of HDAC6
vi

inhibitor plus ibrutinib showed synergistic cell kill in CLL cell lines and patient-derived B cells,
reduced tumor burden, and increased survival in the preclinical CLL mouse model. HDAC6 was
also found to play a role in immunomodulation of CLL B cells and CLL T cells in the
microenvironment. HDAC6 silencing or inhibition modified the expression of immunoreactive
molecules on CLL B and T cells, including programmed cell death (PD)-1, programmed cell death
ligand (PD-L)-1, major histocompatibility complex (MHC)II and lymphocyte-activation gene (LAG)3. Interestingly, alteration of STAT3 signaling was involved in the immunomodulatory activity of
HDAC6. As a result, HDAC6 inhibition resulted in a beneficial reversal of T-cell dysfunction.
Moreover, HDAC6 inhibition augmented the antitumor efficacy of immune checkpoint inhibitor,
anti-PD-1.
B-cell receptor (BCR) and phosphoinositol-3-kinase (PI3K) signaling have emerged as
therapeutic avenues that have changed the paradigm of CLL treatment. Inhibitors targeting these
pathways abrogate survival signaling in B cells, but also can affect other immune compartments.
Secondary immune targets result in a variety of physiological effects that are not thoroughly
understood. On this note, we investigated the role of CLL T-cell subsets in the incidence of
autoimmune-related toxicities occurring in patients treated with PI3K inhibitors idelalisib, duvelisib
and umbralisib. The data established the regulatory T-cell subset (Tregs) as a definitive regulator
of the autoimmune-like toxicities using preclinical CLL and graft-versus-host models. Finally, sideby-side comparison of clinically available PI3K inhibitors demonstrated that umbralisib exhibits
differential and beneficial effects on Tregs through inhibition of casein kinase (CK)-1 epsilon and
canonical Wnt signaling.
The work reported here contributes knowledge and furthers understanding of
immunomodulatory approaches using small-molecule inhibitors for treatment of CLL. While
chemo-immunotherapy is still used and appropriate for selected younger patients, alternative
strategies are sought after for the unfit, elderly, resistant, relapsed and refractory patients. Novel
therapeutic strategies or rational combinations will be most beneficial to those patients who
vii

progress or develop resistance on established regimes. Ultimately, identification of novel targets
and optimization of existing therapies is necessary to increase responses, eradicate minimal
residual disease and mediate toxicity. These processes will advance the treatment regimen for
chronic lymphocytic leukemia patients and impact quality and length of life.
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CHAPTER ONE:
INTRODUCTION

Introduction to cancer
Cancer refers to a collection of related diseases arising from the unchecked proliferation
of a tumorigenic cell. According to the National Cancer Institute (NCI), approximately 38.4% of
people will be diagnosed with cancer at some point in their lifetimes. Malignant tumors may begin
almost anywhere in the human body and can spread through the vascular system to invade a
variety of host tissues, disrupting their normal functions. This can lead to a host of life-threatening
conditions, altogether causing a huge socioeconomic burden in the United States and other
countries around the world. The most common cancers according to 2018 NCI statistics are
breast, lung, prostate, colon, skin, bladder, non-Hodgkin lymphoma, kidney, endometrial,
leukemia, pancreatic, thyroid and liver.
A cancer cell exhibits numerous differences compared to a normal cell. Researchers have
studied and defined these differences over the years, attempting to identify and exploit cancer
cell weaknesses as therapeutic strategies. The “hallmarks” of cancer cells comprise several
universal biological traits acquired during tumorigenesis1. Hallmark traits include sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and metastasis. Further, it is now
widely recognized that tumor beds recruit other types of cells to their physical niches that support
acquisition of hallmarks and ultimately form a tumor microenvironment2.
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Introduction to chronic lymphocytic leukemia (CLL)
Blood cancers are classified as leukemias, lymphomas, or myelomas according to their
cell of origin. Chronic lymphocytic leukemia (CLL), a B-cell malignancy, is the most common
leukemia in the western countries, accounting for approximately one-quarter of new leukemia
cases. It is typical of the aging population and rarely diagnosed in children (average age of
diagnosis was 71 years in 2018). The American Cancer Society estimated 20,940 new cases of
CLL and 4,510 deaths due to CLL in 2018. Although it can be manageable, the disease has a
highly variable clinical course and most patients eventually require therapeutic intervention.
Symptoms can include enlarged lymph nodes, spleen and liver, fatigue, fever, weight loss, night
sweats and frequent infections. In addition, cytopenia and hypogammaglobulinemia are typical.
Risk groups are defined by prognostic score (CLL-IPI) and the Rai and Binet staging systems3, 4.

Immunobiology of CLL B cells
CLL

diagnosis

is

established

with

blood

smear,

lymphocyte

count

and

immunophenotyping of the circulating clonal B cells. The clonal B cells are arrested at the pro Bcell differentiation stage, typically expressing cluster of differentiation (CD)19, dim CD20, CD5
and CD23, while morphologically resembling mature B lymphocytes. CLL B cells also express
dim immunoglobulin (Ig)M and or IgD, with a predominance of either kappa or lambda light chain.
Deletion of chromosome 11q or 17p, p53 mutation, immunoglobulin heavy-chain variable-region
(IgHV) unmutated expression in B cells of CLL patients are standard prognostic markers that can
predict clinical course and resistance to chemotherapy4.
CLL B cells exhibit features that facilitate responses to intrinsic and extrinsic survival
signals. Intrinsic survival signals derive primarily from altered B-cell receptor (BCR) signaling,
resulting in expression of genes that promote a proliferative and anti-apoptotic phenotype5. The
mutational status of surface IgVH on the BCR of CLL B cells is a strong predictor of disease
outcome, where the unmutated subtype is a surrogate of high BCR signaling and indicates
2

shorter time to progression as cells grow more rapidly, whereas the mutated subtype suggests a
more latent disease6. Some evidence suggests a role for autoantigen or microbial antigen
recognition by the BCR in selection and accumulation of the clonal B cells5.
Engagement of the BCR on a CLL B cell induces phosphorylation of its cytoplasmic
regions by src-family kinases, followed by activation of spleen tyrosine kinase (SYK). This triggers
a cascade resulting in activity of 1) Bruton’s tyrosine kinase (BTK), 2) phospholipase-C gamma
(PLC-y), 3) phosphoinositide 3-kinases (PI3Ks) and downstream signaling, 4) mitogen-activated
protein (MAP) kinase and RAS signaling, and 5) transcription factors nuclear factor (NF)-kappaB,
nuclear factor of activated T cells (NF-AT) and AP-15, 7. Therapeutic targeting of BCR-associated
kinases has recently exploded into a major field of interest due to CLL cells’ dependence on tonic
BCR signaling. Notwithstanding, other pathways besides BCR signaling have been intricately
studied and linked to survival of CLL B cells. Notably, therapeutics are being developed to target
receptor tyrosine kinase-like orphan receptor 1 (ROR-1), which activates downstream Wnt
signaling8, 9.
On the other hand, the tumor microenvironment provides extrinsic survival, anti-apoptosis,
and trafficking signals, via secretion of soluble factors and direct interaction with cell surface
ligands. CLL B cells’ ability to respond to interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor
(TNF)a, CD40 ligand (L), BAFF, APRIL, CXCL12 and CXCL13 secreted by the microenvironment
establish that other immune cells play significant roles in pathogenesis of the disease10. This has
led to widespread interest in targeting the CLL immune-microenvironment. Finally, CLL B cells
display the ability to evade tumor immune surveillance. Evidence has shown that CLL B cells can
accomplish this task by modulating immunoreactive surface ligands and cytokines. For example,
CLL B cells upregulate coinhibitory immune checkpoints programmed cell death protein (PD)-1
and PD-L1, downregulate major histocompatibility complex (MHC)II expression and secrete
higher quantities of suppressive cytokines compared to normal B cells, especially IL-1011. These
molecular changes CLL B cells undergo serve to dampen antitumor T-cell responses. Preclinical
3

studies and clinical trials are underway to investigate the utility of checkpoint blockade and
immunomodulatory inhibitors for re-invigorating the antitumor T-cell responses in CLL12.

Figure 1. CLL B cell. Constitutive BCR stimulation and phosphorylation of the intracellular
domain leads to signal transduction through PI3K and BTK signaling. BCR signaling elicits
upregulation of intrinsic survival and anti-apoptosis signals. Altered expression of immunoreactive
surface molecules (e.g. PD-L1 and CD40) and secretion of suppressive soluble factors (e.g. IL10) impact tumor immune evasion abilities and T-cell dysfunction in CLL patients.

Immune Dysfunction in CLL
Due to accumulation of clonal B cells in bone marrow, blood and lymphoid tissue, CLL
patients harbor skewed proportions of other immune cell populations. Immune cells in CLL
patients have been found to exhibit characteristic phenotypes that contribute toward malignant
progression and CLL B-cell survival. Resulting immune dysfunction increases susceptibility to
infections and CLL patients often die from related complications. In addition to the classically
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known bone marrow stromal cells and nurse-like cells that provide extrinsic survival signals for
CLL B cells, abnormal T cells act in collaboration with the microenvironment to support
proliferation of malignant B cells10.
Trends in CLL T-cell changes have emerged: imbalance of T-cell subsets, exhausted
phenotype, dysregulation of coinhibitory molecules, increase in suppressive numbers and
phenotype, abnormal cytokine secretion, immune synapse and toxicity defects. Numerous studies
support the idea of targeting the CLL microenvironment specifically through the T-cell defects to
achieve antitumor effects, and therapies thought to primarily target the CLL B cells have also been
shown to beneficially impact microenvironment populations13, 14, 15. Besides T cells, other immune
populations that are expanded in CLL patients and correlated with disease, such as myeloidderived suppressor cells, are being studied and could be potential targets to augment antitumor
immunity16.

Therapeutic interventions
A variety of approaches has been used to control CLL disease in the past few decades.
In this section, the current major options for CLL treatment will be discussed. Most patients
typically are monitored and do not require treatment. For the symptomatic, patients with
progressive lymphadenopathy or splenomegaly and for patients who develop anemia and
thrombocytopenia, treatment is indicated. Frontline therapy with chemo-immunotherapy
(fludarabine, cyclophosphamide, and rituximab)17 is still used and appropriate for younger patients
that carry a IGHV mutated status, however, less-toxic alternatives are sought after for high risk
younger patients, elderly, unfit or relapsed and refractory (R/R) patients. Elucidation of underlying
molecular pathways driving CLL progression and resistance to therapy has been crucial for
development of revolutionary therapeutics in recent years to address this niche of patients. In
addition, allogeneic stem cell transplant can be a viable option for CLL patients, although it is very
limited by age3.
5

CLL therapies can be divided into several broad categories: chemotherapy,
immunotherapy, and targeted therapies. Chemotherapies typically utilized for CLL treatment are
the DNA-damaging agents chlorambucil, fludarabine, and bendamustine. These work by
preferentially preventing the replication of tumor cells. Due to frequent relapse and resistance, it
has been advantageous to combine immunotherapy with chemotherapy. Several monoclonal
antibodies (mAb) against CD20 antigen are clinically approved, including rituximab, ofatumumab,
and obinutuzumab. These work to increase cell-dependent and antibody-dependent cellular
cytotoxicity3. In addition to the CD20 antigen, mAbs that target a slew of CLL B cell surface
proteins are in development (Table 1).
Other immunotherapeutic agents are being investigated with the intention of augmenting
host immunity. Pembrolizumab, an anti-PD1 immune checkpoint-blocking antibody, is in clinical
trial for R/R CLL patients alone or in combination with ibrutinib18. Notably, pembrolizumab elicited
response in 4 out of 9 CLL patients who progressed after ibrutinib treatment and developed
Richter’s transformation18, a phenomenon where B-CLL becomes fast-growing diffuse large Bcell lymphoma (DLBCL). Atezolizumab (anti-PD-L1 antibody) was found to block progression in
a preclinical CLL mouse model and is currently in clinical trial in combination with obinutuzumab
and ibrutinib for relapsed, refractory, or high-risk untreated CLL

19

. Numerous other immune

checkpoints have been shown to be upregulated in CLL that function to dampen immune
responses and evade immune surveillance20. Preclinical development of therapeutics capable of
checkpoint inhibition is therefore burgeoning. Last but not least, chimeric antigen receptor (CAR)
T cells bearing domains recognizing CD19 and additional signaling through 4-1BB or CD28 have
demonstrated efficacy in clinical trials with refractory CLL patients

21

. Several types of CAR T

therapies are in clinical trial for CLL, utilizing autologous or allogeneic T cells recognizing various
domains. Recently, interest has been generated in utilizing immunomodulatory small-molecule
inhibitors to reconfigure the phenotype of CLL patient T cells, so that they are more conducive to
ex vivo expansion and transduction with CAR constructs22. Preclinical studies surrounding this
6

concept are underway and will provide rationale to combine CAR therapy with small-molecule
inhibitors.
The third group of CLL therapeutics encompasses the small-molecule inhibitors. The BCR
kinase inhibitors have gained most attention in this group. Approval of ibrutinib (BTK inhibitor), a
first-in-class, once-daily treatment by the United States Food and Drug Administration (FDA) as
frontline therapy for CLL patients shifted the paradigm of CLL treatment23. Idelalisib (PI3Kd
inhibitor) in combination with rituximab has also been approved for R/R patients24. Most recently,
duvelisib (PI3Kd/g inhibitor) was approved for R/R CLL patients who failed at least two prior
therapies. Alternative BCR inhibitors are being tested in clinical trial but are not yet approved for
CLL, such as acalabrutinib25 (BTK), entospletinib (SYK) and umbralisib26 (PI3Kd/casein kinase
(CK)1e). Another small-molecule inhibitor at the forefront is venetoclax, targeting the B-cell
lymphoma (BCL)-2 protein, a key regulator of apoptosis. Venetoclax

27

has been approved for

CLL patients alone or in combination with rituximab after one prior therapy and has shown
promising initial results in combination with ibrutinib as well as obinutuzumab for frontline
therapy28. Although venetoclax combination offers a time limited therapy, there are not enough
data to know whether these patients will progress. Several other small-molecule inhibitors
targeting various CLL survival proteins are in clinical development, including HDAC inhibitors
(Table 1).
BCR inhibitors have been shown to display immunomodulatory effects, and can robustly
target secondary immune populations like T cells and myeloid cells12. The effects of BCR
inhibitors on secondary target populations are under investigation. These studies will elucidate
novel mechanisms of action, unveil potential repurposing and provide rationale for combinations.
Lenalidomide (targeting cereblon), although not a BCR inhibitor, is a small-molecule
immunomodulatory drug that exhibits antitumor effects in CLL while changing the immune
microenvironment to increase immune surveillance. Studies demonstrating immunomodulation of

7

CLL immune subsets by lenalidomide have paved the way for elucidating the immunomodulatory
effects of BCR inhibitors29.
Table 1: In-clinic CLL therapeutics. Notable chemotherapy, immunotherapy, and smallmolecule inhibitors for treatment of CLL that are either approved or in Phase I-III trial (2018).
Therapy

Class

Status

Chlorambucil

alkylating agent

FDA approved

Fludarabine

purine analog

FDA approved

Bendamustine

purine analog

FDA approved

Cyclophosphamide

purine analog

FDA approved

Rituximab

anti-CD20 mAb

FDA approved

Ofatumumab

anti-CD20 mAb

FDA approved

Obinutuzumab

anti-CD20 mAb

FDA approved

Ublituximab

anti-CD20 mAb

Phase III

Pembrolizumab

anti-PD-1 mAb

Phase I/II

Nivolumab

anti-PD-1 mAb

Phase I/II

Atezolizumab

anti-PD-L1 mAb

Phase II

Alemtuzumab

anti-CD52 mAb

FDA approved

Cirmtuzumab

anti-ROR1 mAb

Phase I

Monalizumab

anti-NKG2A mAb

Phase I/II

Daratumumab

anti-CD38 mAb

Phase II

Lirilumab

anti-KIR mAb

Phase I

Ianalumab

anti-IgG1 mAb

Phase I

Idelalisib

PI3K𝛅 inhibitor

FDA approved

Duvelisib

PI3K𝛅𝛄 inhibitor

FDA approved

Buparlisib

pan-PI3K inhibitor

Phase II

Umbralisib

PI3K𝛅/CK1𝛆 inhibitor

Phase III

AMG-319

PI3K𝛅 inhibitor

Phase I

Ibrutinib

BTK/ITK inhibitor

FDA approved

Acalabrutinib

BTK inhibitor

Phase III

Tirabrutinib

BTK inhibitor

Phase II

Zanubrutinib

BTK inhibitor

Phase III

Spebrutinib

BTK inhibitor

Phase I

Fenebrutinib

BTK inhibitor

Phase I

Selinexor

XPO1 inhibitor

Phase I

Entospletinib

SYK inhibitor

Phase II

Ruxolitinib

JAK inhibitor

Phase II

AZD6738

ATM/ATR inhibitor

Phase I/II

8

Table 1 Cont’d: In-clinic CLL therapeutics. Notable chemotherapy, immunotherapy, and smallmolecule inhibitors for treatment of CLL that are either approved or in Phase I-III trial (2018).

Pevonedistat

NEDD8-activating enzyme inhibitor

Phase I

CYC065

CDK2/9 inhibitor

Phase I

Venetoclax

BCL-2 inhibitor

FDA approved

Navitoclax

BCL-2/BCL-xL/BCL-w inhibitor

Phase I/II

Lenalidomide

thalidomide analog

FDA approved

ACY-1215

HDAC6 inhibitor

Phase I

Vorinostat

pan-HDAC inhibitor

Phase I/II

Romidepsin

pan-HDAC inhibitor

Phase I

MS-553

PKC-β inhibitor

Phase I

Axicabtagebe ciloleucel

anti CD19 CAR T

Phase I/II

Tisagenlecleucel-T

anti CD19 CAR T

Phase I

Lisocabtagene maraleucel

anti CD19/4-1BB CAR T

Phase I/II

CD19/CD22 CAR T

anti CD19/CD22 CAR T

Phase I

CD19.CAR-aNKT cells

CAR T/ NKT

Phase I

INVAC-1

DNA vaccine

Phase II

NeoVax

personal neoantigen vaccine

Phase I

CD3/28 activated T cells

adoptive cell

Phase I/II

Introduction to epigenetics
Epigenetics is the study of heritable changes in gene expression occurring without
alteration to primary DNA sequence. Chromatin refers to the macromolecular complex of DNA
and histone proteins which comprise the genome. The nucleosome, the unit of chromatin,
contains 147 base pairs of DNA wrapped around a histone octamer. The histone octamer contains
two histones H2A, H2B, H3 and H4. The components of the nucleosome can be covalently
modified, altering the structural organization and expression of genes. Noncovalent modifications
also occur. Epigenetic dysregulation of biological processes such as transcription, DNA repair,
and replication, have been found to occur frequently in cancer30. In addition, therapeutics targeting
epigenetic regulators have demonstrated anticancer activity.
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In total, there are numerous types of DNA and histone modifications that are regulated by
chromatin-modifying enzymes. DNA methylation refers to the addition of methyl groups to CpG
islands in the genome. This is catalyzed by DNA methyltransferases (DNMTs)31. This modification
generally represses transcription and ensures stability by silencing transposable elements. A link
between cancer and epigenetics was first observed from DNA methylation studies, mostly
characterizing silencing of tumor suppressors by promoter methylation. Aside from DNA
methylation, post-translational histone modifications have been characterized, including
methylation, acetylation, phosphorylation, ubiquitination and others32. Modifications to histone
tails regulate gene expression by changing chromatin to a condensed or relaxed conformation.
Acetylation of histone tails is regulated by enzymes called histone acetyl transferases
(HATs) and histone deacetylases (HDACs). HATs and HDACs catalyze the addition or removal
of an acetyl group derived from acetyl-CoA at the N-terminal amino group of lysine residues,
respectively. Acetylation neutralizes the positively charged lysine and relaxes chromatin structure
to encourage transcription, while deacetylation condenses chromatin structure to block
transcription33. HATs and HDACs, along with numerous binding partners, have been found to be
dysregulated in some types of cancer34. Alteration of cancer cell processes through targeting of
HATs and HDACs has therefore been a major field of interest.

Histone deacetylases
Eighteen mammalian histone deacetylases have been identified, which can be divided
into classes according to structural homology33. Class I includes HDACs 1, 2, 3 and 8. Class IIa
includes HDACs 4, 7 and 9, while class IIb includes HDACs 6 and 10. Class II HDACs show
tissue-specific expression and both nuclear and cytoplasmic localization- suggesting that this
class may regularly acetylate non-histone proteins. The newest HDAC member, HDAC11, is the
only member of class IV. Finally, class III comprises sirtuins 1-7. The expression levels of various
HDACs have been found to be dysregulated in numerous cancer types35. These findings suggest
10

that transcriptional regulation by aberrant HDACs could be a common phenomenon in tumor
initiation. The role of HDACs in cancer may also depend on their regulation of non-histone
proteins. For example, tumor suppressor p53 activity has been shown to be affected by
acetylation status which can be modulated by pharmacological inhibition of HDACs36.

HDAC inhibitors
The potential for epigenetic manipulation of cellular processes makes HDACs compelling
targets for therapeutics. In addition, HDAC inhibitors have been used as tools to elucidate the
cellular activities of the HDAC family of proteins. Some HDAC inhibitors block the entire family of
proteins and are referred to as “pan-HDAC inhibitors”. Others specifically silence one HDAC or a
class of HDACs, referred to as “specific” or “selective” HDAC inhibitors. Four pan-HDAC inhibitors
are currently FDA-approved for treatment of specific malignancies: vorinostat (SAHA) and
romidepsin for cutaneous T-cell lymphoma, belinostat for peripheral T-cell lymphoma, and
panobinostat for multiple myeloma. Several others are in clinical trials for various cancer types,
including hematological malignancies and solid tumors37. The HDAC inhibitors in clinical trial as
anticancer agents current for 2018 is summarized in Table 2. Many more are in preclinical
development37.
It is now recognized that mechanisms of action responsible for the antitumor effects of the
HDAC inhibitors differ. For example, HDAC inhibitors have been shown to cause cell cycle arrest,
induce apoptosis, reduce angiogenesis, and downregulate oncogenic signaling in cancer cells38.
In preclinical studies, the HDACs have been shown to regulate various processes depending on
cell type and disease context. Notably, several HDACs have been implicated in control of immune
responses and as a result, HDAC inhibitors are being explored as immunomodulatory agents39.
Some pan-HDAC inhibitors tested in patients have not progressed past clinical trials due to
toxicity. Toxicity with pan-HDAC inhibitors is not altogether surprising, given the wide range of
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HDAC expression and function. For this reason, growth of isoform-selective HDAC inhibitors is
currently at the forefront40. Since the aberrant expression and function of individual HDACs in
cancers may differ, isoform-selective inhibitors can be utilized for potent and specific targeting.
The use of selective HDAC inhibitors promises more deliberate, rationale-based trials leading to
less toxicity, greater efficacy, mechanistic understanding, novel utility, and combination
approaches with other therapeutics.

Table 2: HDAC inhibitors in clinical trial as anticancer agents (2018).
HDAC inhibitor

Class

Disease

Vorinostat

pan-HDAC

melanoma, solid tumors, uterine sarcoma, NSCLC, CLL

Panobinostat

pan-HDAC

melanoma, NHL, multiple myeloma, AML, MDS

Abexinostat

pan-HDAC

follicular lymphoma

Romidepsin

pan-HDAC

lymphoid malignancies

Givinostat

pan-HDAC

chronic myeloproliferative neoplasms

Tefinostat

pan-HDAC

hepatocellular carcinoma

Mocetinostat

Class I HDAC

melanoma, solid tumors, NSCLC

Entinostat

Class I HDAC

solid tumors, MDS, CML, AML, breast cancer

CUDC-907

Class I/II HDAC / PI3Ka,
B, d

solid tumors

Martinostat

Class I/IIb HDAC

breast cancer

KA2507

HDAC6

solid tumors

ACY-241

HDAC6

NSCLC, multiple myeloma

ACY-1215

HDAC6

lymphoid malignancies, breast cancer, multiple myeloma
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NOTE TO THE READER

Portions of the following chapter have been previously published: Maharaj, K et al. Silencing of
HDAC6 as a Therapeutic Target in Chronic Lymphocytic Leukemia. Blood Advances 2, 30123024 (2018)41 and have been included here with the journal’s permission (see Appendix A for
copyright policy).
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CHAPTER TWO:
SILENCING OF HDAC6 AS A THERAPEUTIC STRATEGY IN CHRONIC
LYMPHOCYTIC LEUKEMIA

Introduction
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly
changing, the disease remains incurable, and resistance, relapsed disease, and partial responses
persist as significant challenges. Recent studies have uncovered roles for epigenetic modification
in the regulation of mechanisms contributing to malignant progression of CLL B cells. However,
the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients
remains poorly explored. We report for the first time that expression of epigenetic modifier histone
deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic
mouse models compared to HDAC 6 in normal controls. Genetic silencing of HDAC6 conferred
survival benefit in euTCL1 mice. Administration of isoform-specific HDAC6 inhibitor ACY738 in
the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed
disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis.
Further, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell
lines and improved overall survival compared to either single agent in vivo. These results
demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclinical
CLL models and suggest a rationale for the clinical development of HDAC6 inhibitors for CLL
treatment, either alone or in combination with Bruton’s tyrosine kinase inhibition.
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Background and rationale
Epigenetic reprogramming in CLL B cells has previously been described in several
studies42, 43, 44. These studies documenting DNA hypomethylation, dysregulated microRNAs, and
histone modifications in CLL B cells have proven beneficial in identifying biomarkers and have
offered a fresh perspective on therapeutic strategies. Our group has also reported findings
establishing a role for epigenetic modifiers in altering CLL biology15, 45. Epigenetic modification
with demethylating agent 5-aza-2’deoxycytidine and HDAC inhibitor LAQ824 restored the
immunogenicity of CLL cells through the induction of antigenic markers to facilitate interaction of
CLL B cells and T cells. Demethylation of T helper 1 promoters by 5-aza-2’deoxycytidine
repolarized T helper 2-skewed CLL T cells to a more beneficial inflammatory phenotype.
Interestingly, various groups have reported elevated HDAC expression in CLL B cells compared
to HDAC expression in normal B cells and correlations of HDAC expression levels with prognostic
factors46, 47, 48, 49. Several studies have also begun to explore the therapeutic potential of HDAC
inhibitors for CLL treatment50, 51. However, the roles of individual HDACs in CLL biology have not
been fully elucidated.
Class IIb HDAC6 can form a complex with nuclear proteins such as p300,52 HDAC11,53
Runx2,54 and LCoR55 to regulate transcriptional repression. On the other hand, HDAC6 can
deacetylate cytoplasmic proteins alpha-tubulin,56 cortactin,57,

58

HSP90α,59 and GRP78,60

regulating cell motility, migration, division, and proteosomal degradation61. Further, HDAC6 has
been explored in the context of various cancers. It was found to be upregulated in oral squamous
cell carcinoma,62 ovarian carcinoma,63,

64

and primary acute myeloid leukemia,65 relative to

nonmalignant controls. Preclinical studies have demonstrated that HDAC6 inhibitors display
antitumor activity when used either alone or in combination with other agents to treat multiple
myeloma,66, 67 B-cell lymphoma,60, 68 breast cancer,69, 70 lung cancer,71, 72 and melanoma73, 74. At
present, HDAC6-selective inhibitors are in clinical trials to treat several solid tumor types, multiple
myeloma, and lymphoma (NCT03008018, NCT02935790, NCT20635061, NCT01323751,
15

NCT02091063)75. Finally, HDAC6 has been explored in the context of immune regulation76, 77. In
the current study, we asked whether there is a role for HDAC6 in CLL B-cell pathobiology and
explored the potential therapeutic value of targeting HDAC6 in preclinical CLL models.

Results
Analysis of HDAC6 expression in CLL patient samples
We examined the expression of HDAC6 in peripheral blood samples from a cohort of 38
CLL donors and 13 healthy donors. Table 3 displays clinical features of all CLL patients. PBMCs
were gated on normal B cells (CD19+ CD5-) in healthy donors and CLL B cells (CD19+ CD5+) in
CLL donors (Figure 2). HDAC6 protein expression was determined by flow cytometry and
quantified by median fluorescence intensity. HDAC6 protein expression was found to be
upregulated in CLL B cells compared to normal healthy donor B cells (Figure 3A). Correlation
analyses demonstrated a weak positive association between HDAC6 protein expression and
CD19+ CD5+ CLL B-cell percentages in CLL patient samples (Figure 3B). In addition, HDAC6
protein expression was higher among CD38+ patients than CD38- patients (Figure 3C). However,
HDAC6 protein expression did not correlate with gender (p = .2), age at diagnosis (p = .6), del
11q/ATM gene (p = .2), del 17p/p53 gene (p = .7), del 13q (p = .5), trisomy 12 (p = .7), ZAP70
status (p = .4), immunoglobulin heavy chain variable region-mutated/unmutated status, or
relapsed status (p = .9; data not shown).
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Table 3. CLL patient characteristics

Patient ID

Gender

Age at
Diagnosis

Cytogenetics
(FISH)

CD38
Expression
>7%

ZAP70
Expression
>10%

IgVH
Status

Relapsed

CLL1

Female

47

trisomy 12

-

-

Unmutated

Yes

CLL2

Female

50

normal

-

-

Mutated

No

CLL3

Female

71

del 13q, del 17p

+

+

Mutated

No

CLL4

Male

51

trisomy 12

-

-

Mutated

Yes

CLL5

Male

62

del 13q

-

Unknown

Mutated

No

CLL6

Female

59

trisomy 12

Unknown

+

Unknown

Yes

CLL7

Male

58

del 11q, del 13q

+

+

Unmutated

Yes

CLL8

Male

39

del 11q

+

Unknown

Mutated

Yes

CLL9

Male

61

del 13q

-

-

Mutated

No

CLL10

Female

62

normal

-

-

Mutated

No

CLL11

Female

55

trisomy 12

-

Unknown

Unmutated

Yes

CLL12

Male

57

del 13q

+

-

Mutated

No

CLL13

Male

46

del 11q, del 13q

-

-

Unmutated

No

CLL14

Male

56

del 13q

+

+

Mutated

No

CLL15

Male

69

del 11q, del 13q

Unknown

Unknown

Mutated

No

CLL16

Male

58

del 13q

+

-

Unknown

No

CLL17

Male

61

del 13q

-

-

Mutated

No

-

-

Unknown

Yes

CLL18

Female

49

del 13q, del 17p,
del 12

CLL19

Male

65

homozygous 13q

+

-

Unmutated

No

CLL20

Female

56

normal

-

-

Unmutated

No

CLL21

Male

46

del 11q

-

-

Unknown

No

CLL22

Female

39

trisomy 12

+

-

Mutated

No

CLL23

Male

64

trisomy 12

+

-

Mutated

No

CLL24

Male

53

normal

+

+

Mutated

No

CLL25

Male

77

del 13q, del 17p

-

-

Mutated

No

CLL26

Female

74

trisomy 12

-

-

Mutated

No

-

-

Unknown

No

CLL27

Male

49

IgH
rearrangement

CLL28

Female

49

del 11q, del 13q

+

-

Mutated

No

CLL29

Female

46

del 13q

Unknown

-

Mutated

No

CLL30

Male

61

del 11q, del 13q

-

-

Mutated

No

CLL31

Female

60

del 13q

-

-

Unmutated

No

CLL32

Male

65

normal

+

-

Unknown

No

CLL33

Female

76

normal

-

+

Unmutated

No

+

Unknown

Unmutated

No

Unknown

Unmutated

Yes

CLL34

Female

49

del 11q, IgH
rearrangement

CLL35

Male

52

normal

Unknown

CLL36

Female

55

del 13q

+

-

Mutated

No

CLL37

Male

56

del 13q

-

Unknown

Mutated

No

CLL38

Female

57

del 11q, del 13q

+

-

Unmutated

No

17

A

B

CLL Patient PBMCs

Normal donor PBMCs

Figure 2. Flow cytometry analysis of CLL patient and normal peripheral blood mononuclear
cells (PBMCs). Cells of interest were gated on singlets using forward scatter height vs. forward
scatter area parameters and nonviable cells (Live Dead Yellow-positive) were excluded. Median
fluorescence intensity of HDAC6 was determined for the CD19+ CD5+ (CLL B cells) population.
All markers were gated according to fluorescence-minus-one or isotype controls. HDAC6
fluorescence-minus-one control is indicated as grey histogram. Red arrows denote the order of
gating strategy. (A) Representative of CLL patient cells analysis. (B) Representative of normal
donor cells analysis. Abbreviations: CLL, chronic lymphocytic leukemia; PMBC, peripheral blood
mononuclear cells.
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Figure 3. Analysis of HDAC6 expression in CLL patient samples. (A) Intracellular HDAC6
protein expression in CD19+ CD5- B cells from normal donors (n = 13) and CD19+ CD5+ B cells
from CLL patient peripheral blood samples (n = 38), as determined by flow cytometry. (B)
Correlation analyses showing relationship between HDAC6 protein expression and CLL B-cell
percentages in CLL patient samples. (C) HDAC6 protein expression in CD38+ or CD38- CLL
patient samples. Error bars correspond to standard deviations and *, **, *** represent p < .01, p
< .001, p < .001, respectively. Abbreviations: CLL, chronic lymphocytic leukemia; HDAC6, histone
deacetylase 6; MFIR, median fluorescence intensity ratio (value normalized to isotype control).
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Genetic silencing of HDAC6 in the euTCL1 murine model
To study the role of HDAC6 in CLL B cells, we employed the euTCL1 transgenic murine
model. This mouse model is genetically engineered to express the T-cell leukemia 1 (TCL1) gene
in B cells, leading to development of a CLL-like phenotype at 6 to 9 months of age.78 At 6 months
of age, euTCL1 mice demonstrated higher expression of HDAC6 protein in peripheral CD19+ B
cells compared to age-matched wild-type (WT) mice (Figure 4B, 5A). Here, we generated an
HDAC6-deficient euTCL1 mouse model by crossing euTCL1 mice with HDAC6KO mice. In
euTCL1/HDAC6KO mice, HDAC6 protein levels were significantly decreased and TCL1 protein
expression in B cells remained unchanged compared to euTCL1 mice. We also detected
increased acetylation of a-tubulin in HDAC6-deficient mice,56 suggesting that HDAC6 was
functionally impaired (Figure 4D). Age-matched cohorts of euTCL1 and euTCL1/HDAC6KO mice
were observed for survival alongside WT and HDAC6KO controls. Interestingly, the
euTCL1/HDAC6KO cohort demonstrated increased overall survival (median survival, 375 days)
compared to euTCL1 controls (median survival, 318.5 days; Figure 5B). However,
euTCL1/HDAC6KO mice eventually succumbed to leukemia.
To determine the effect of HDAC6 genetic deletion on CLL burden, 9-month-old mice were
sacrificed for the collection of spleens and peripheral blood. We quantified tumor burden by gating
on CD3- CD19+ B220Lo-Hi CD5+ B cells (Figure 6). The total B-cell number (CD19+ B220Lo-Hi) was
lower in the euTCL1/HDAC6KO group than the euTCL1 group, in both peripheral blood and
spleen compartments. In addition, the ratio of CD5+ B cells (defined as “malignant”) to CD5- B
cells (defined as “normal”) was reduced in the euTCL1/HDAC6KO group compared to the euTCL1
group. The reduction in malignant/normal B-cell ratios was evident in both peripheral blood and
spleen (Figure 5C). Finally, splenomegaly, was reduced in euTCL1/HDAC6KO mice compared to
euTCL1 controls (Figure 5D-E). Genetic deletion of HDAC6 therefore slowed down the
accumulation of malignant B cells in vivo, resulting in lower CLL tumor burden over time and
improved overall survival rates.
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HDAC6KO (MFI 897)

HDAC6KO (7%)
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euTCL1/HDAC6KO (67.4%)
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Wildtype (34%)

Acetylated alpha-tubulin

Figure 4. Analysis of HDAC6-deficient CLL mouse model. (A) Western blot showing
expression of HDAC6 protein in WT, euTCL1, HDAC6KO or euTCL1/HDAC6KO murine B cells.
(B) Flow cytometry showing expression of HDAC6 protein in WT, euTCL1, HDAC6KO or
euTCL1/HDAC6KO murine B cells. (C) Flow cytometry analysis showing TCL1 protein expression
is similar in euTCL1 B cells and euTCL1/HDAC6KO B cells. (D) Flow cytometry analysis showing
functional inhibition of HDAC6 in euTCL1/HDAC6KO B cells demonstrated by increased
acetylation of alpha-tubulin, a cytoplasmic substrate of HDAC6, compared to the WT cohort.
Abbreviations: CLL, chronic lymphocytic leukemia; WT, wild-type mouse.
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Figure 5. Genetic silencing of HDAC6 in euTCL1 mice. (A) Intracellular HDAC6 protein
expression in CD19+ B220+ B cells from WT or euTCL1 peripheral blood, as determined by flow
cytometry (n = 9 per group). (B) Overall survival of indicated groups of mice (n = 5 per group),
representing results of 3 independent experiments. (C) CLL burden quantified in peripheral blood
or spleen by flow cytometry (n = 5 per group), representing results of at least 3 independent
experiments. (D) Compilation of spleen-weight data at the end of the study (n = 3 per group). (E)
Representative spleens from each group indicated. Abbreviations: CLL, chronic lymphocytic
leukemia; HDAC6, histone deacetylase 6; MFIR, median fluorescence intensity ratio; PB,
peripheral blood; WT, wild-type mice.
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euTCL1 mice

A.

euTCL1/HDAC6KO mice

B.

Figure 6. Quantification of tumor burden in CLL mice. Flow cytometry analysis of tumor
burden in splenocytes of (A) euTCL1 and (B) euTCL1/HDAC6KO mice. Cells of interest were
gated on singlets using forward scatter height vs. forward scatter area parameters, and nonviable
cells (4',6-Diamidino-2-Phenylindole, Dihydrochloride -positive) were excluded. The CD3- CD19+
B220+ CD5- were gated as normal B cells and CD3- CD19+ B220+ CD5+ were gated as
malignant CLL B cells. CD5 fluorescence-minus-one control is displayed as grey dots. Red arrows
denote the order of gating strategy.
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RNA sequencing of HDAC6-deficient murine CLL B cells
Next, we investigated transcriptional changes related to disease progression in HDAC6deficient CLL B cells. RNA-sequencing was performed on B cells isolated from spleens of young
(3-month-old) and aged (9-month-old) cohorts of euTCL1, euTCL1/HDAC6KO, HDAC6KO, and
WT mice. Gene expression patterns in young mice differed from aged mice. Hierarchal clustering
demonstrated

that

gene

expression

was

most

dissimilar

between

euTCL1

and

euTCL1/HDAC6KO in both young and aged groups, suggesting that silencing of HDAC6 initiated
widespread transcriptional changes in the CLL setting (Figure 7). In euTCL1 mice, CLL
progresses as the mice age. Therefore, gene expression in aged euTCL1 may depend heavily on
both the aging process and disease progression. Consequently, young and aged WT and
HDAC6KO mice were compared in order to identify and eliminate genes that were differentially
expressed due to the aging process.
Figure 8A-B describes the analyses of the changed genes uniquely regulated in
euTCL1/HDAC6KO mice compared to euTCL1 mice as a consequence of slower disease
progression. The Venn diagram in Figure 8C depicts the group of 334 disease-related genes that
were uniquely regulated in euTCL1/HDAC6KO mice compared to euTCL1 mice. Gene ontology
analysis was performed on these 334 genes. The majority of the 50 pathways corresponded to
immune-related signaling. Spleen tyrosine kinase (SYK) was common among many of these
pathways and was one of the most significantly changed genes within the focus group. It was
confirmed by quantitative real-time PCR that SYK is transcriptionally downregulated in
euTCL1/HDAC6KO and HDAC6KO mice compared to euTCL1 and WT mice, respectively (Figure
9A). Interestingly, SYK is involved in transduction of BCR signaling, which is required for the
survival of CLL B cells.79 Given the importance of SYK to BCR signaling, this result suggested to
us that transcriptional regulation of SYK might potentially result in changes to downstream BCR
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signaling in CLL B cells lacking HDAC6. Immunoblotting confirmed that SYK protein was
downregulated in euTCL1/HDAC6KO mice compared to euTCL1 mice (Figure 9B).

A

Young group
Top 50 expressed genes

B

Aged group
Top 50 expressed genes

Figure 7. Hierarchical clustering of top 50 differentially expressed genes. Heat maps show
similarities in gene expression patterns among mice used in RNA-sequencing analyses. (A)
Young group. (B) Aged (old) group.
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A

B

C

Figure 8. RNA-sequencing analysis of young and old mice. (A) Table showing cohorts of mice
used for analysis and types of genes identified by each. (B) Flow chart describing step-by-step
analysis process used to identify genes of interest. (C) Venn diagram displaying the number of
differentially expressed genes either exclusive to or common to each cohort. The Venn diagram
was used in the identification of genes of interest.
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Figure 9. SYK expression. (A) SYK mRNA expression in aged mice (n = 3 per group) normalized
to 18s control gene. (B) Western blot showing expression of SYK protein in isolated murine B
cells (from spleens) along with graphed densitometry of bands (n = 3 mice per group).
Antitumor efficacy of ACY738 in murine CLL
Considering the results described, we asked whether selective HDAC6 inhibition could be
harnessed for therapeutic benefit in CLL. First, orally bioavailable selective HDAC6 inhibitor
ACY738 was incorporated into chow and fed to WT mice at levels equivalent to a final
concentration of 25 mg/kg per day. At this concentration, ACY738 was detected in plasma (Figure
10A), and acetylation of a-tubulin was increased in the ACY738-treated group compared to a
group fed chow (vehicle) alone (Figure 10B), confirming reduction of HDAC6 enzymatic activity
with ACY738 oral treatment. ACY738-treated WT mice did not lose weight or show other signs of
drug-related toxicities (data not shown). Percentage of normal CD19+ B cells, CD3+ T cells,
CD4/CD8 ratio, and lymphocyte activation in spleen were not significantly affected after 1 month
of continuous ACY738 treatment (Figure 10C).
Next, groups of aging euTCL1 mice were treated with ACY738 or were fed vehicle alone,
beginning at 3 months of age until either death or euthanasia due to disease symptoms. Similar
to HDAC6-deficient euTCL1 mice, ACY738-treated euTCL1 mice displayed significantly longer
overall survival compared to mice fed vehicle only (Figure 11A). Figure 11B displays the gross
changes in percentage of B and T cells observed in the periphery of these mice. Specifically,
tumor burden and malignant-to-normal B-cell ratios were decreased in peripheral blood and
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spleen samples following 3 months of treatment (Figure 11C). To extend these results, this
experiment was replicated in the adoptive transfer euTCL1 model. In this model, leukemic
euTCL1 splenocytes were injected into 6- to 8-week-old WT mice to establish CLL disease within
3 weeks of engraftment. Mice were then randomized to ACY738 or vehicle groups. ACY738
treatment significantly prolonged overall survival in this model as well (Figure 11D). Finally, in
mice sacrificed at the end of the experimental period (12 weeks after adoptive transfer), onset of
CLL was delayed, and splenomegaly was reduced in the ACY738 group compared to the vehicleonly group (Figure 11E-G). Taken together, these data suggest that pharmacological inhibition of
HDAC6 with ACY738 had resulted in a therapeutic benefit in our CLL models.

Figure 10. In vivo activity of selective HDAC6 inhibitor ACY738 in wildtype mice. Peripheral
blood and spleens were collected from wild-type mice after 1 month of being fed vehicle (n = 4)
or treated with ACY738 orally at 25 mg/kg (n = 5). (A) Plasma was separated by centrifugation
from whole blood, and the presence of ACY738 was detected by high-performance liquid
chromatography. (B) Acetylation level of alpha-tubulin was quantified via flow cytometry in
peripheral blood CD19+ B cells from indicated mice (n = 4 per group). (C) Characterization of
immune subsets and activation status from splenocytes (n = 4 per group).
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Figure 11. In vivo activity of selective HDAC6 inhibitor ACY738 in CLL mice. (A) Overall
survival for euTCL1 aging (n = 7 per group) mice fed vehicle only or treated with ACY738. Data
is representative of 3 independent experiments. (B) Characterization of immune subsets from
splenocytes derived from aging euTCL1 mice treated with vehicle or ACY738 orally (n = 7 per
group). (C) CLL burden was quantified in aging euTCL1 mice fed vehicle only or treated with
ACY738 for a duration of 3 months (n = 6 per group). Data were compiled from 2 independent
experiments. (D) Overall survival for adoptive transfer euTCL1 mice (n = 6 per group) fed vehicle
only or treated with ACY738. Data is representative of 3 independent experiments. (E) CLL
burden was also quantified in adoptive transfer CLL mice (n = 8 per group) fed vehicle only or
treated with ACY738 for a 12-week duration, and results are representative of 5 independent
experiments. (F) Compilation of adoptive transfer CLL mice spleen weights after 12 weeks of
indicated treatments (n = 6 per group). (G) Representative spleens from indicated groups. Error
bars correspond to standard errors of the means and *, **, *** represent p < .01, p < .001, p <
.001, respectively, compared to vehicle-only controls. Abbreviations: CLL, chronic lymphocytic
leukemia; conc, concentration; HDAC6, histone deacetylase 6; MFI, median fluorescence
intensity; PB, peripheral blood; WT, wild-type mice.
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ACY738 treatment alters proliferative capacity and sensitivity to apoptosis in
euTCL1 B cells
To investigate the direct effects of pharmacological HDAC6 inhibition on CLL B cells,
euTCL1 splenocytes were injected into SCID mice, which intrinsically lack B and T cells. Mice
were randomized into 2 groups treated with ACY738 or fed vehicle only. Rapid expansion of
adoptively transferred euTCL1 B cells was detected in peripheral blood 7 days after transfer.
However, oral ACY738 treatment significantly attenuated the expansion of malignant B cells over
time (Figure 12A). This led us to hypothesize that ACY738 may directly affect intrinsic survival
signals of malignant B cells, creating a cytostatic effect and, therefore, a more indolent less
aggressive disease. To test this hypothesis, all animals were sacrificed after 21 days of treatment
and B cells were isolated from splenocytes by negative selection. First, the proliferative status of
B cells was measured by Ki67 staining, and as expected, it was significantly reduced in the
ACY738 treatment group compared to the vehicle-only group (Figure 12B). In addition, isolated
B cells from these mice were cultured ex vivo with lipopolysaccharide for 72 hours. B cells from
ACY738-treated mice were found to be more sensitive to lipopolysaccharide-induced apoptosis
than B cells in untreated mice, as measured by annexin V and viability staining (Figure 12C-D).
The malignant phenotype of CLL B cells depends on constitutive activation of molecular
pathways that promote proliferation, resistance to apoptosis, and survival signals. BCR signaling
is one of the most crucial pathways that CLL B cells depend on for intrinsic survival signals. Within
this pathway, Bruton’s tyrosine kinase (BTK) is constitutively activated in CLL and is a critical
kinase for CLL development and expansion.80 To examine whether activation status of this
pathway was impaired, phosphorylation of BTK was measured following ex vivo stimulation with
antimouse immunoglobulin M in the isolated B cells. Phosphorylation of BTK was found to be
decreased in the ACY738 group compared to the vehicle-only group (Figure 12E). These results
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suggested that ACY738 treatment reduced BCR signaling in the malignant B cells, possibly
disrupting downstream proliferation and antiapoptotic signals.

D

Figure 12. Effect of in vivo ACY738 treatment on euTCL1 B cells. (A) euTCL1 B cells were
injected into SCID mice, which were then fed vehicle only or treated with oral ACY738 (n = 6 per
group). Tumor burden was quantified in peripheral blood at the time points indicated. Data are
representative of 2 independent experiments. (B) Total B cells were isolated from spleens of
immunocompromised adoptive transfer CLL mice. Proliferative capacity was measured by Ki67
staining and flow cytometric analysis (n = 5 per group). (C) Isolated B cells were cultured with 1
μg/mL of lipopolysaccharide for 72 hours and the percentage of apoptotic B cells was quantified
by Annexin V staining (n = 3 mice per group). (D) B cells were stimulated ex vivo with 10 μg/mL
of antimouse immunoglobulin M, and phosphorylated Bruton’s tyrosine kinase (Y223) was
analyzed by flow cytometry (vehicle-only group, n = 6 and ACY738-treated group, n = 5). Error
bars correspond to standard errors of means and *, **, *** represent p < .01, p < .001, p < .001,
respectively. Abbreviations: p-BTK, phosphorylated Bruton’s tyrosine kinase; FI, median
fluorescence intensity; PB, peripheral blood; SCID, severe combined immunodeficient; WT, wildtype mice.
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HDAC6 inhibition also alters proliferation and apoptosis in human CLL via
downregulation of BCR signaling
To validate the relevance of these results in the human setting, 2 aggressive patientderived CLL cell lines were treated with ACY738 in vitro to selectively inhibit HDAC6 (Figure 13A).
Figure 12B displays a heat map showing the selectivity of ACY738 for HDAC6 compared to other
HDACs. The CLL cell lines OSU-CLL and Mec2 were found to express HDAC6 protein at higher
levels than normal healthy human donor B-cell controls (Figure 14A). First, these cell lines were
cultured with ACY738 or dimethyl sulfoxide (DMSO) control.
Growth kinetics were significantly delayed in ACY738-treated cells (Figures 14B and 13C)
with reduced cell-cycle progression and arrest in G1 phase (Figures 14C and 13D). Additionally,
CLL cells experienced increased, dose-dependent apoptosis following treatment with ACY738
relative to DMSO (Figures 14D-E and 13E). To further examine the role of BCR signaling in
altering CLL proliferation after HDAC6 inhibition, we measured the phosphorylation status of
several BCR-signaling molecules after ACY738 treatment.
Phosphorylation of several BCR-signaling molecules was dose-dependently abrogated in
CLL cell lines after ACY738 treatment compared to phosphorylation in DMSO-treated controls
(Figures 14F and 13F). Considering these results, we looked at MCL1 and BCL-2, transcription
factors which mediate resistance to apoptosis in CLL cells.81 Both MCL1 and BCL-2 levels were
reduced following 24 hours of culture with ACY738, in a dose-dependent manner (Figures 14G
and 13G).
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Figure 13. HDAC6-selective range of ACY738 in CLL cell lines. (A) OSU-CLL and Mec2 were
treated with ACY738 in increasing concentrations for 24 hours, and flow cytometry analysis was
performed to detect acetylation status of alpha-tubulin and histone 3 in viable cells. Increased
acetylation of alpha-tubulin compared to histone 3 indicated selectivity for HDAC6 inhibition (B)
Heat map showing biochemical potency of ACY738 for HDAC1-9 compared to pan-HDAC
inhibitor panobinostat and another HDAC6 selective inhibitor, ACY1215. (C) Growth kinetics of
Mec2 in culture with ACY738 at 1 μM or vehicle for indicated period. (D) Cell cycle analysis in
Mec2 determined by Ki67/7AAD staining after 24 hours of indicated treatments. (E) Apoptosis
was measured by Annexin V/viable staining following treatment of Mec2 with ACY738 for 24
hours. (F) Phosphorylation of indicated molecules was measured following stimulation with 10
μg/mL antihuman immunoglobulin M in Mec2. (G) Expression of intracellular MCL1 and BCL-2
protein analyzed by flow cytometry, after incubating Mec2 with indicated concentrations of
ACY738.
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Figure 14. Effect of ACY738 treatment in human CLL cell lines. (A) HDAC6 protein expression
quantified by flow cytometry in normal donor B cells (n = 5) and CLL cell lines; data were compiled
from 3 independent experiments. (B) Growth kinetics of OSU-CLL in culture with ACY738 at 1 μM
or vehicle for indicated period. (C) Cell cycle analysis in OSU-CLL determined by Ki67/7AAD
staining after 24 hours of indicated treatments. (D-E) Apoptosis was measured by Annexin
V/viable staining following treatment of OSU-CLL with ACY738 for 24 hours. (F) Phosphorylation
of indicated molecules was measured following stimulation with 10 μg/mL antihuman
immunoglobulin M in CLL cell lines. (G) Expression of intracellular MCL1 and BCL-2 protein
analyzed by flow cytometry, after incubating OSU-CLL with indicated concentrations of ACY738.
All error bars correspond to standard deviations and *, **, *** represent p < .01, p < .001, p < .001,
respectively. Abbreviations: CLL, chronic lymphocytic leukemia; HDAC6, histone deacetylase 6.
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Synergistic activity of ACY738 and ibrutinib in vitro
Due to the antiproliferative and proapoptotic effects of HDAC6 inhibition, we hypothesized
that combining HDAC6 and BTK (ibrutinib) inhibitors would be beneficial for CLL therapy. Indeed,
combining ACY738 and ibrutinib demonstrated synergistic cell kill in both OSU-CLL and Mec2
cells in vitro (Figure 15A-B). To determine whether this was relevant in primary cells, we cultured
CLL patient samples with ACY738, ibrutinib, or both. Single treatments decreased viability dosedependently, however the combination further decreased viability compared to single treatments.
Decreased viability was more noticeable in the unmutated patients, suggesting that patients with
a more proliferative disease may particularly benefit from this combination (Figure 15C).

C

Viability %

Viability %

A

B

Figure 15. Combinatorial efficacy of ACY738 and ibrutinib in CLL cells in vitro (A) CellTiterBlue assay was performed to detect cell kill synergy in CLL cell lines treated with ACY738 and
ibrutinib. (B) CellTiter-Blue assay was performed to detect cell kill in CLL patient peripheral B cells
with unmutated or mutated IGVH status after 48 hours of indicated treatments (n = 8 patients per
group). All error bars correspond to standard deviations and *, **, *** represent p < .01, p < .001,
p < .001, respectively. Abbreviations: CLL, chronic lymphocytic leukemia; IgVH, immunoglobulin
variable heavy chain region.
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Combinatorial efficacy of ACY738 and ibrutinib in murine CLL in vivo
To assess the in vivo relevance of this drug combination, groups of adoptively transferred
euTCL1 mice were treated with ACY738 alone, ibrutinib alone, or ACY738 in combination with
ibrutinib, or fed vehicle only from disease engraftment until death or euthanasia. Prior to these
experiments, we confirmed that WT mice treated with ibrutinib via the drinking water had exhibited
reduced phosphorylation of BTK in isolated splenic B cells after only 3 days of ibrutinib treatment
(Figure 16). First, longer overall survival was confirmed in both the ACY738-only and ibrutinibonly groups, as compared to the vehicle group. However, the combined treatment further
increased overall survival compared to either single-agent treatment group (Figure 17A). Median
survival of the dual treatment group was 194 days compared to 112.5 days for the ACY738-only
group and 138.5 days for the ibrutinib-only group. When sacrificed after 12 weeks, tumor burden
and splenomegaly were observed to be lower in the dual-treatment group (Figure 17B-C) than in
either single-agent group (Figure 17D-E). Mice on dual treatment did not overtly exhibit any
symptoms associated with drug-related toxicities, such as weight loss or diarrhea (data not
shown). These results suggested that dual inhibition of HDAC6 and BTK showed combinatorial
antitumor efficacy against CLL in this murine model.
anti-mouse IgM

-

+

-

+

BTK

pBTK
(Y223)
GAPDH
WT (vehicle) WT (ibrutinib)

Figure 16. Functional activity of ibrutinib drinking water. Western blot showing activity of
ibrutinib delivered via drinking water. WT mice (n = 3 per group) were supplied with ibrutinib
drinking water or regular drinking water (vehicle) for 3 days. Mice were sacrificed, and total B cells
were isolated by magnetic separation from homogenized splenocytes. Phosphorylation of BTK at
Y223 was measured following 30 minutes of stimulation with plate-bound antimouse IgM (10
μg/mL).
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Figure 17. Combinatorial antitumor efficacy of ACY738 and ibrutinib treatment in CLL mice.
(A) Overall survival data for adoptive transfer CLL mice treated as indicated until death or
euthanasia (n = 8 per group), representative of 2 independent experiments. (B-C) CLL burden
was quantified in peripheral blood or spleen after 12 weeks of indicated treatments; data are
representative of 3 independent experiments. (D) Spleen weight at conclusion of experiment. (E)
Representative spleens from indicated treatment groups are shown. Error bars correspond to
standard errors of means and *, **, *** represent p < .01, p < .001, p < .001, respectively.
Abbreviations: CLL, chronic lymphocytic leukemia; PB, peripheral blood.

Discussion
In this study, we found that protein expression of HDAC6 was elevated in B cells of CLL
patients compared to normal B-cell controls (Figure 3). Previously, Van Damme et al
demonstrated that HDAC6 messenger RNA was found to be higher in CLL patient B cells
compared to normal B-cell controls. In addition, HDAC6 mRNA expression was found to correlate
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with treatment-free survival but not with CD38, ZAP70, or IgVH status48. In our study, HDAC6
protein expression was higher in CD38+ patients compared to CD38- patients. CD38+ CLL
patients typically represent a population of intermediate- to high-risk patients. It is interesting to
note that, in separate studies, both HDAC6 mRNA and protein were found to be elevated in CLL
B cells. Our data also showed elevation of HDAC6 protein in CLL cell lines (Figure 14) and
euTCL1 B cells (Figure 5) compared to normal controls. The discrepancies between these studies
may be due to differences in methods. Protein level was measured via flow cytometry in the
current study, whereas mRNA level was measured via qRT-PCR in Van Damme et al. In addition,
cohort size and average CLL B-cell percentage present in the patient samples were different
between the 2 studies. Altogether, our current observations and the prior literature suggested that
HDAC6 expression may be a clinically relevant factor for CLL patients and warrants further
investigation to determine whether HDAC6 may be able to regulate processes supporting the
malignant progression of CLL B cells.
Our experiments showed that HDAC6 inhibition downregulated BCR signaling in murine
and human CLL B cells, leading to defects in proliferation and sensitivity to apoptosis. This
translated to delayed disease progression, lower tumor burden, and increased overall survival
when HDAC6 was genetically silenced or pharmacologically inhibited in the euTCL1 model.
Molecules such as BTK and AKT that are constitutively activated downstream of the BCR are
particularly crucial to transduction of oncogenic signaling in CLL B cells.82, 83, 84, 85, 86 HDAC6 has
been shown to regulate oncogenic mitogen-activated protein kinase- and phosphoinositide 3
kinase-signaling pathways in multiple cell types via deacetylation of cytoplasmic targets. 5 In our
experiments, we found no evidence of hyperacetylation of SYK, BTK, or AKT following HDAC6
inhibition in CLL cell lines (data not shown). However, RNA-seq analyses demonstrated
transcriptional regulation of several genes that may be involved in CLL progression. Of note, SYK
was included in this list. Given the importance of SYK to BCR signaling transduction, this result
indicated to us that HDAC6 might be acting in the nucleus to regulate the expression of this
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kinase, thereby affecting downstream BCR signaling. Indeed, SYK protein was downregulated in
euTCL1/HDAC6KO mice compared to euTCL1 mice (Figure 9). Although the exact mechanism
is not yet clear, we have further studies that are fully exploring this possibility.
Single-agent therapy with BCR inhibitors has met with clinical success; however, relapsed
patients are emerging as a population with unmet needs. Characterization of mutations in BCRsignaling components, such as BTK (C481S) and/or PLC-2γ, has shown a role for these
components in resistance to ibrutinib. Further characterization also found genetic alterations of
TRAIL-R, EP300, MLL2, and EIF2A in ibrutinib-resistant patients. Mutations could be detected for
up to 15 months before manifestation of clinical progression, and these patients were transitioned
to alternative targeted agents with moderate success.70 A study of clonal evolution in 8 patients
who were resistant to venetoclax (BCL-2 inhibitor) reported mutations in BTG1 and BRAF
deletions affecting CDKN2A and amplification of CD274 (PD-L1).87 A recently reported study
classified acquisition of Gly101Val mutation in BCL2 as a resistance mechanism to venetoclax.88
Other researchers have predicted that resistance to venetoclax may occur via upregulation of
alternative antiapoptotic BCL-family proteins. Resistance to idelalisib mechanisms (PI3Kδ
inhibitors) have been predicted to occur, for example, via upregulation of class 1A PI3K.89
Recently reported data showed mutations in mitogen activated pathway kinase (MAPK) genes
occurring in CLL patients treated with PI3K inhibitors.90 In these patients, idelalisib treatment did
not downregulate IgM-induced extracellular signal-regulated kinase (ERK) 1/2 phosphorylation.
Combination approaches with other inhibitors were recommended to be tested in these patients.
Combination approaches using ibrutinib are being tested in previously treated high-risk patients
and in treatment-naïve patients (e.g. NCT02301156, NCT02420912, NCT02756897). Results
reported after six months of a clinical trial testing ibrutinib plus venetoclax in relapsed and
refractory (R/R) CLL showed high overall response rates, eradication of minimal residual disease,
and manageable adverse events.91 Although results are promising, long-term follow-up has not
been reported, and it is not known whether some of these patients may ultimately progress.
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In conclusion, this study establishes for the first time the potential therapeutic value of
pharmacological HDAC6 inhibition for CLL treatment. ACY738 and ibrutinib demonstrated greater
cell kill than either single treatment in CLL B cells, particularly in patients with unmutated IgVH,
and significant combinatorial antitumor efficacy in our preclinical CLL models. Despite
improvements in care, CLL currently remains incurable and demonstrates a variable course with
many R/R patients. In anticipation of the drawbacks of the currently available therapies, it is
imperative to develop alternative inhibitors and rational combination approaches to cater for the
niche that does not respond or experiences progression on available regimens. One strategy
being explored to combat ibrutinib-resistance is combination with immunotherapy or inhibitors
whose antitumor efficacy results from a differentiated mechanism of action. Given our preclinical
data, we believe selective HDAC6 inhibitors are promising candidates for this niche and are
worthy of further testing either alone, in combination with BTK inhibitors, or as an alternative
therapeutic agent for R/R patients.

Materials and methods
CLL patient samples
Peripheral blood mononuclear cells (PBMCs) were obtained from patients with chronic
lymphocytic leukemia (CLL). All participants gave written institutional review board-approved
informed consent for their blood to be used for research (#CR6_Pro00000316). Blood was
collected at the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). CLL patients
were diagnosed according to International Workshop on CLL 2018 guidelines.92 Patients indicated
as “relapsed” in Table 1 had been previously treated with chemotherapy at the time of sample
collection. All other patients were treatment-naïve at the time of sample collection.
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In vivo studies
An HDAC6-deficient CLL murine model (referred to as euTCL1/HDAC6KO) was
generated by crossing HDAC6KO and Eu-TCL1 (C57BL/6 background) mice78,

93

. For the

accelerated CLL model, several aged leukemic euTCL1 mice (“aged leukemic” is defined as > 9
months of age and showing > 70% CD5+ B cells out of total viable lymphocytes by flow analysis)
were sacrificed and their splenocytes were pooled. Freshly obtained splenocytes were then
resuspended in phosphate-buffered saline and adoptively transferred via tail vein into 6- to 8week old C57BL/6 wild-type (WT) mice at 25 x 10^6 per mouse. In severe combined
immunodeficient (SCID) mice, leukemic splenocytes were injected at 5 x 10^6 per mouse (WT- or
SCID-recipient animals were purchased from Charles River, Wilmington, MA). CLL induction was
confirmed at 3 weeks after adoptive transfer by high complete blood count, and a significantly
greater CD19+ B220+ CD5+ B lymphocyte population in peripheral blood than in peripheral blood
from a healthy age-matched WT cohort. Groups were randomized prior to treatment. For survival
analyses, mice were monitored until death or euthanasia due to disease symptoms such as
lethargy, difficulty moving, lack of grooming, and enlarged spleen and/or lymph nodes. Mice were
kept in pathogen-free conditions and handled in accordance with Guidelines for Animal
Experiments requirements.
Cell culture
Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1%
penicillin-streptomycin, 1% nonessential amino acids, and MycoZap (Lonza, Basel, Switzerland).
Cell lines were authenticated prior to use in these assays. Cells were incubated in 5% CO2 at
37°C for the duration of assays.
Cell viability assay
Cell-kill assays for viability and synergy studies were conducted using CellTiter-Blue Cell
Viability Assay (Promega, Madison, WI). Cells were plated at a density of 1 x 106/mL in a 96-well
flat-bottom plate and treated with inhibitors in a final volume of 100uL for 24 hours prior to the
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addition of CellTiter-Blue reagent. Synergy was determined by combination index. The
combination index method is based on that previously described,94 in which a combination index
value of 0.85 to 0.9 indicated slight synergism, 0.7 to 0.85 indicated moderate synergism, 0.3 to
0.7 indicated synergism, 0.1 and 0.3 indicated strong synergism, and < 0.1 indicated very strong
synergism.
Ex vivo murine CLL-B cell studies
Murine B cells were isolated from homogenized splenocytes by negative selection, using
magnetic separation (B-cell Isolation Kit; StemCell Technologies, Vancouver, Canada). To detect
proliferation or B-cell receptor signaling activation, B cells were stimulated by plate-bound goat
antimouse immunoglobulin M F(ab’)2 fragment (Southern Biotech, Birmingham, AL) for 50
minutes, prior to fixing for flow cytometry assessment.
B-cell receptor activation in CLL cell lines
Mec2 or OSU-CLL were cultured with ACY738 for 24 hours then stimulated with platebound goat antihuman immunoglobulin M F(ab’)2 fragment (Southern Biotech, Birmingham, AL)
for 50 minutes prior to fixing for flow cytometry assessment.
Immunoblotting
Samples were analyzed by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel
electrophoresis), followed by transfer to nitrocellulose membrane blocked with 5% nonfat milk and
incubation with indicated antibodies. Blots were developed using LI-COR system. Cell lysis was
performed with radioimmunoprecipitation assay buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 10% glycerol) supplemented with
protease inhibitors (Roche, Basel, Switzerland) and phospho-protease inhibitors (Santa Cruz,
Dallas, TX). Quantities of proteins were determined by bicinchoninic acid assay (Pierce, Waltham,
MA). Antimouse antibodies were used against pBTK-Y223, BTK (Cell Signaling, Danvers, MA),
and GAPDH (ThermoFisher Scientific, Waltham, MA).
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Flow cytometry
For murine CLL immunophenotyping, 100 µL of peripheral blood was obtained from
submandibular bleeds and fresh spleens were homogenized and resuspended in an equal volume
of flow cytometry (FACS) buffer prior to analysis. Cells were stained with indicated antibodies
according to manufacturers’ dilutions for 1 hour at room temperature. To complete phospho-flow,
cells were stimulated then fixed/permeabilized in 1% BD CytoFix for 15 minutes followed by 90%
ice-cold methanol for 1 hour. Cells were stained with the phospho-specific antibody or isotype
control for 1 hour prior to analysis in FACS buffer in the presence of Fc block. For intracellular
staining, cells were fixed/permeabilized using transcription factor fixation/permeabilization buffer
set (BD Biosciences, San Jose, CA), in accordance with manufacturer’s protocol. Cell cycling was
achieved by fixing cells in ice-cold 80% ethanol dropwise and incubating them at -20°C overnight
followed by Ki67 staining (BD Biosciences, San Jose, CA). Acquisition was performed on an LSRII
Cytometer (BD Biosciences, San Jose, CA), and data were analyzed with FlowJo software v10.1
(Tree Star Inc., Ashland, OR).
RNA Sequencing
Isolated splenic B cells from 3 young (3-month-old) and 3 aged (9-month-old) mice per
group (euTCL1, euTCL1/HDAC6KO, HDAC6KO, and WT) were lysed in Trizol, and messengerRNA extraction was performed. Normalized expression data from DESeq2 were log transformed.
Samples were divided into 2 groups by age (young and old). For each group, top-expressed genes
were used to create hierarchical cluster analyses.
Reverse transcription and polymerase chain reaction
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). Complementary
DNA was synthesized from RNA using iScript Reverse Transcriptase (BioRad, Hercules, CA).
Primers against mouse SYK and mouse 18s (Qiagen, Venlo, Netherlands) were used together
with iScript Reaction Mix (BioRad, Hercules, CA).
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Reagents and Antibodies
ACY738 was supplied by Acetylon Pharmaceuticals, Boston, MA. All other inhibitors used
in experiments were commercially obtained. All inhibitors used for in vitro assays were dissolved
in dimethyl sulfoxide and stored as 20 mM stock at -20°C.
For murine studies, ACY738 was incorporated into chow at 25 mg/kg and administered to
mice orally. Ibrutinib was dissolved in drinking water with 10% cyclodextrin at a final concentration
of 15 mg/kg per day per mouse and administered orally, in accordance with a previously
established protocol.80
For immunophenotyping analysis of murine CLL, DAPI (4',6-diamino-2-phenylindole,
dihydrochloride) exclusion was used for viability staining. Antimouse antibodies were used against
CD3 BV786, CD19 Alexa Fluor 700, CD5 PerCP, immunoglobulin M PE, CD4 Pacific Blue, CD8
FITC, CD69 BUV737 (BD Biosciences, San Jose, CA), and B220 Alexa Fluor 488 (Biolegend,
San Diego, CA). Absolute cell counts were determined using Accucheck counting beads
(ThermoFisher Scientific, Waltham, MA), following the manufacturer’s protocol.
For phospho-flow analysis, antibodies were used against pBTK-Y223, pAKT-S473, pERKT202/Y204 (BD Biosciences, San Jose, CA), and pSyk-Y525/526 (Cell Signaling, Danvers, MA),
conjugated to Alexa Fluor 647. Phospho-IKK α/β-S176/180 (Cell Signaling, Danvers, MA) was
used with antirabbit secondary antibodies conjugated to Alexa Fluor 647.
For assessment of HDAC6 expression in CLL patient samples, antibodies were used
against HDAC6 Alexa Fluor 488 (Novus Biologicals, Centennial, CO), acetylated alpha-tubulin
PE (Cell Signaling, Danvers, MA), CD19 Alexa Fluor 647, and CD5 PerCP (BD Biosciences, San
Jose, CA). Frozen aliquots of CLL peripheral blood mononuclear cells were thawed and allowed
to recover at 37°C in RPMI media with 50% fetal bovine serum for 1 hour. Samples were fixed
using nuclear transcription factor staining buffer set (BD Biosciences, San Jose, CA) in
accordance with the manufacturer’s protocol. Cells were stained in the presence of human Fc
block (BD Biosciences, San Jose, CA).
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For apoptosis assays, cells were stained with Annexin V BV605 (BD Biosciences, San
Jose, CA) and Live Dead Near Infrared (ThermoFisher Scientific, Waltham, MA) in the presence
of annexin V staining buffer, in accordance with the manufacturer’s protocol.

Statistical analyses
For normally distributed data, statistical significance of comparisons between data sets
was determined by unpaired 2-tailed Student’s t test or 1-way ANOVA followed by Tukey’s
multiple comparisons test. For data that did not demonstrate normal distribution, Mann-Whitney
U unpaired test or 1-way ANOVA followed by Kruskal-Wallis test were used. Kaplan-Meier
survival curves were compared using the log-rank test. Overall survival was defined as time from
birth until death or euthanasia in the aged euTCL1 model or time from leukemic adoptive transfer
until death or euthanasia in the accelerated model. For correlation studies, linear regression was
performed on data sets. A p value < .05 was considered significant. All analyses were conducted
using GraphPad Prism software v7.
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CHAPTER THREE:
HDAC6 INHIBITION RELIEVES CLL T-CELL DYSFUNCTION AND AUGMENTS
ANTITUMOR EFFICACY OF ANTI-PD-1

Introduction
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune
dysfunction characterized by exhausted T cells. As a result, CLL patients are severely susceptible
to infectious complications that increase morbidity and mortality. T cell exhaustion, immune
checkpoint upregulation and increase of suppressive T cells contribute to an immunosuppressive
microenvironment. It has been postulated that reversal of T-cell dysfunction in CLL may be
beneficial to reduce tumor burden. Here, we report for the first time that selective HDAC6 inhibition
exerts immunomodulatory effects on CLL B cells and relieves immunosuppression of CLL T cells.
In the euTCL1 murine model genetically lacking HDAC6 or treated with ACY738 (HDAC6
inhibitor), PD-L1 protein expression and IL-10 production was decreased on CLL B cells. This
occurred alongside a reversal of the exhausted T-cell phenotype, demonstrated by alteration of
coinhibitory molecules and activation status. Our experiments suggest these effects may be
mediated through downregulation of the STAT3 pathway in the CLL B cells. Based on the
beneficial immunomodulatory activity of HDAC6, we rationalized that HDAC6 could be combined
with immune checkpoint blockade in CLL. Indeed, combination treatment with ACY738
augmented the antitumor efficacy of anti-PD-1 in the euTCL1 model. Taken together, these data
highlight a role for HDAC inhibitors in combination with immunotherapy. Specifically, HDAC6
inhibition together with checkpoint inhibition should be investigated for use in CLL patients to
reduce tumor burden while relieving T-cell dysfunction.
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Background and rationale
CLL T-cell dysfunction has been rigorously documented both in patients and the euTCL1
murine model95, 96. Dysfunctional CLL T cells serve two main purposes: 1) they support tumor
immune evasion and 2) provide survival and expansion signals to the malignant clone. In
particular, T-cell exhaustion and upregulation of immune checkpoint inhibitors has been
implicated in evasion of tumor immune surveillance97. Additionally, increased regulatory T cells
(Tregs) suppress T effector function. Based on these observations, it has been postulated that
reversal of T-cell dysfunction may reinvigorate T-cell driven, anti-CLL cytolytic activity. T-cell
changes occurring alongside CLL progression have been reviewed in detail in Chapter 212.
Several studies have explored the idea of reversing T-cell exhaustion in CLL. Brusa et al
initially identified that the PD-1/PD-L1 axis drives T-cell exhaustion in CLL98. This study reported
that PD-L1HI CLL cells and associated closely with PD-1+ T cells in lymphoid tissue. Gassner et
al found that pretreatment of euTCL1 splenocytes with recombinant PD-1 blocking fragments
reduced engraftment of disease when these cells were adoptively transferred to wildtype
recipients. This study concluded that the antitumor effects were due to T-cell based tumor cell
lysis99. In another study, McClanahan et al characterized CLL-specific PD-1 induction on euTCL1
T cells. Interestingly, the PD-1+ T cells exhibited variable effector function100. This group also
reported antitumor efficacy of PD-L1 blocking antibody in the euTCL1 model19.
Anti-PD-1 antibodies pembrolizumab and nivolumab have demonstrated clinical activity in
solid tumors and are being tested in CLL. In a Phase II trial, pembrolizumab elicited responses in
4 out of 9 CLL patients who had underwent Richter transformation (RT) but 0 out of 16 patients
who had relapsed after prior therapy with ibrutinib without RT18. Increased PD-L1 on B cells and
a trend of increased PD-1 on T cells were detected in responders versus non-responders before
therapy. However, levels of other checkpoints were not determined. Nivolumab in combination
with ibrutinib also elicited responses in CLL patients that underwent RT101. These results suggest
that PD-1 blockade may be useful for RT patients. For the non-RT, relapsed CLL patients, further
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optimization will be required. We speculated that in relapsed CLL patients, multiple mechanisms
of immune suppression and possible upregulation of numerous immune checkpoints may occur.
We therefore hypothesized that novel combination approaches with other agents that block
immune checkpoints could maximize efficacy of anti-PD-1.
CLL cells in circulation contain constitutively phosphorylated signal transducer and
activator of transcription 3 (STAT3) at serine 727 residues102. STAT3 can also be phosphorylated
at tyrosine 705 residues when CLL cells are stimulated with extracellular factors. IL-6, IL-10, and
IgM stimulation have been shown to initiate transient STAT3 phosphorylation at the tyrosine 705
residue in CLL cells. Phosphorylated STAT3 undergoes nuclear localization and activates
expression of anti-apoptosis genes.
Roles for histone deacetylases in cancer-related immune biology have been reported by
our group and others. HDAC6 inhibition has been found to augment immunogenicity of melanoma
cells through modulation of STAT3/PD-L173. HDAC6 was also found to regulate the activity of the
STAT3/IL-10 pathway in antigen-presenting cells77. More recently, we have described the
antitumor activity of histone deacetylase 6 (HDAC6) inhibition in CLL41. However, the therapeutic
potential for combination of HDAC inhibition with immunotherapy remains unexplored to this date.
In the current study, we investigated the immunomodulatory effects of HDAC6 in CLL and tested
the rational combination of ACY738 (HDAC6 inhibitor) with anti-PD-1 antibody in vivo.

Results
Reduction of PD-L1 on CLL B cells by HDAC6i
To examine the role of HDAC6 in CLL immunomodulation, we utilized the euTCL1
adoptive transfer model. Aged euTCL1 or euTCL1/HDAC6KO splenocytes were injected into
syngeneic wildtype recipients. After engraftment was confirmed, a group of euTCL1 recipients
was treated orally with selective HDAC6 inhibitor, ACY738, or vehicle. Both ACY738-treated and

48

euTCL1/HDAC6KO recipient mice exhibited less CLL progression after six weeks compared to
controls (Figure 18A).
Previous studies by other groups have demonstrated increased expression of PD-L1 on
CLL B cells compared to normal controls. In our euTCL1 adoptive transfer experiment, PD-L1
was found to be upregulated on the malignant B cell subset (CD5+) compared to the normal B
cell subset (CD5-, Figure 18B). PD-L1 expression also correlated with tumor burden, confirming
a role for the PD-1/PD-L1 axis in driving CLL progression in this model (Figure 18C). Notably, we
observed that PD-L1 expression was significantly decreased on ACY738-treated and
euTCL1/HDAC6KO total and malignant B cells, and trended down in normal B cells (Figure 18B).
To determine if modulation of PD-L1 was a general antitumor aftereffect, or a direct effect
of HDAC6 inhibition, we treated wildtype mice orally with ACY738 or ibrutinib as a positive control.
Ibrutinib has previously been shown to downregulate PD-L1 in B cells11. All treated mice
downregulated PD-L1 on B cells (Figure 18D).
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Figure 18. Immunoregulation of CLL B cells by HDAC6. Peripheral blood mononuclear cells
(PBMCs) were collected and stained with appropriate antibodies for 1 hour at room temperature.
(A) Tumor burden (malignant B cells) was defined as CD19+ B220LO IgM+ CD5+ cells. Total B
cells were gated as CD3- CD19+ cells. Normal B cells were gated as CD19+ B220HI CD5- cells.
(B) PD-L1 expression on total, malignant and normal B cells. (C) Correlation analysis of PD-L1
and total B cells. (D) WT mice were treated with ACY738 or ibrutinib orally for 3 weeks. Expression
of PD-L1 on CD19+ B220HI B cells from periphery. n = 8 mice per group. Results are
representative of 3 independent experiments. Data are expressed as average and error bars
represent standard error of mean. gMFI: geometric mean fluorescence intensity; PB: peripheral
blood. *p<0.05, **p<0.005, ***p<0.0005.
Reversal of CLL T-cell phenotype by HDAC6i
Expression of immune checkpoints PD-1 and LAG-3 was downregulated on both CD4+
and CD8+ subsets in the periphery (Figure 19A-D). Although HDAC6KO mice demonstrated a
reduction of absolute T cells, CD4-to-CD8 ratios were not changed by HDAC6 silencing or
ACY738 (Figure 19E). Ratio of memory subsets was also not changed in the periphery (Figure
20A). Interestingly, PD-1 and LAG-3 was also downregulated on CD8+ effector memory T cells
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(Figure 20B). Finally, the absolute number of regulatory T cells (Tregs) was reduced along with
checkpoint expression (Figure 20C-F).
Next, T cells were isolated from splenocytes and differentiation factors were assessed by
q-RT-PCR. Compared to euTCL1 mice, euTCL1/HDAC6KO and ACY738-treated mice favored
the Th1 phenotype. Expression of Tbet, a transcription factor involved in T helper (Th) 1 lineage
differentiation, as well as IL-2, was substantially increased on euTCL1/HDAC6KO T cells, and on
ACY738-treated euTCL1 T cells to a lesser extent (Figure 21A-B). Expression of Eomes (Th2
transcription factor) was decreased on euTCL1/HDAC6KO T cells and ACY738-treated euTCL1
T cells (Figure 21C).
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Figure 19. EuTCL1 T-helper and cytotoxic-T phenotype. PBMCs were stained with appropriate
antibodies for 1 hour at room temperature. Cells were gated on singlets, CD3+ viable cells, CD4+,
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Figure 20. EuTCL1 Memory-T and Treg phenotype. PBMCs were stained with appropriate
antibodies for 1 hour at room temperature. Cells were gated on singlets, CD3+ viable cells, CD4+,
and CD8+. (A) CD8+ memory subsets were defined as naïve (CD25- CD44-), terminal (CD25-,
CD44+) and effector (CD25+ CD44+) in accordance with a previously published strategy for
euTCL1 mice. (B-C) Immune checkpoint expression on CD8+ effector memory T cells. (D)
Absolute Treg count. Tregs were defined as CD4+ CD25HI CD127- cells. (E-F) Immune
checkpoint expression on Tregs. n = 8 per group. Results are representative of 3 independent
experiments. Data are expressed as average and error bars represent standard error of mean.
Significant p values are in bold type or *p<0.05, **p<0.005, ***p<0.0005.
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Figure 21. Analysis of euTCL1 T-helper subsets. CD3+ T cells were isolated from spleens
using magnetic separation (negative selection) and lysed in Trizol. RNA was extracted and qRTPCR was performed using indicated primers. (A) Expression of Tbet (B) Expression of IL-2 (C)
Expression of Eomes. n = 3 per group. Data are expressed as average and error bars represent
standard deviation. *p<0.05, **p<0.005, ***p<0.0005.
HDAC6i counters CLL-induced T-cell suppression
It has been previously established that CLL B cells suppress T cell responses. At this
point, we asked whether inhibition of HDAC6 in CLL B cells could reverse suppression of T-cell
responses. To answer this question, a mixed lymphocyte assay was conducted. EuTCL1 B cells
were isolated from spleens and pretreated with HDAC6 inhibitor ACY1215, washed and
cocultured with OTII CD4+ T cells in the presence of OVA peptide. Interferon gamma (IFNg) was
measured as a readout of T-cell activation. ACY1215 pretreatment of B cells dose-dependently
increased T cell-activation (Figure 21A). This data suggested that HDAC6 inhibition was able to
counter the immunosuppressive effects of CLL B cells. These effects were further confirmed in
human CLL cell lines co-cultured with activated normal, human T cells (Figure 21B-C).
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Figure 21. T-cell activation in co-culture with CLL B cells. (A) EuTCL1 B cells were isolated
from spleens by magnetic separation (negative selection) and pretreated overnight with
ACY1215. Then B cells were washed and plated together with OTII CD4+ T cells in a 1:5 ratio.
Stimulation was achieved by addition of OVA peptide. Concentration of IFNg secreted into
supernatant was measured by cytokine bead array after 24 hours. (B) Mec2 or OSU-CLL cells
were pretreated with ACY1215 overnight, washed, and co-cultured with normal human T cells in
a 1:5 ratio. Stimulation was achieved by addition of anti-CD3/28 dynabeads. Concentration of
IFNg secreted into supernatant was measured by cytokine bead array after 24 hours. Results are
typical of three independent experiments.
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Combinatorial efficacy of ACY738 and anti-PD-1
Given that HDAC6 silencing or inhibition relieved CLL T-cell dysfunction in vivo, we
rationalized that it may be beneficial to combine HDAC6 inhibition with immune checkpoint
inhibition in CLL. For this experiment, euTCL1 adoptive transfer mice were treated with either
ACY738, PD-1, or both. CLL burden was sampled in the periphery of mice. Both ACY738 and
PD-1 treatment singlehandedly reduced CLL progression. Compared to either single agent,
combination of ACY738 and anti-PD1 treatment further decreased CLL progression (Figure 22A).
Previously, anti-PD-1 treatment was shown to demonstrate antitumor activity through
increasing tumor-specific cytolysis99. Here, we hypothesized that relief of T-cell exhaustion by
ACY738 treatment may augment the antitumor activity of T cells in PD-1 treated mice. To examine
this hypothesis, mice were sacrificed and T cells were assessed from spleens. The combination
of PD-1 and ACY738 induced a trend of increased percentage of antigen-experienced cytotoxic
T cells (CD8+ CD44+, Figure 22B) In addition, the ratio of CD107a and perforin-expressing CD8+
CD44+ T cells were increased in the combination treatment group (Figure 22C-D). These results
suggest greater effector T function in the combination group leading to increased antitumor
activity.
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Figure 22. Combinatorial efficacy of ACY738 and anti-PD-1 in euTCL1 model. (A) Tumor
burden in euTCL1 mice. Peripheral blood lymphocytes were stained with indicated antibodies for
1 hour at room temperature and populations were detected by flow cytometry. (B-D) Effector T
cells and function. Mice were sacrificed and splenocytes were homogenized and lysed for red
blood cells. Remaining cells were stained with indicated antibodies for 1 hour at room temperature
prior to fixing, perming, and staining with antibodies to detect intracellular antigens for 1 hour at 4
degrees Celsius. To assess function, effector markers are expressed as the ratio of CD44+
CD107a/perforin expressing cells to negative cells out of the CD8+ gate. n = 8 per group. Data
are expressed as mean and error bars depict standard deviation. Significant p values are in bold
type or *p<0.05, *p<0.005, *p<0.005.
Alteration of STAT3 signaling in CLL B cells by HDAC6i
HDAC6 has been found to alter STAT3/IL-10 pathway in antigen-presenting cells. STAT3
signaling is also active in CLL B cells and has previously been determined to control PD-L1
expression after ibrutinib treatment. We therefore examined whether STAT3 signaling was
affected after HDAC6 inhibition in CLL B cells. Ex vivo, we observed that ACY-treated or
euTCL1/HDAC6KO B cells secreted less IL-10 compared to euTCL1 B cells (Figure 23A). Next,
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activation of STAT3 pathway was assessed by detection of phosphorylated STAT3 protein at
serine 727 and tyrosine 705. In euTCL1 B cells, HDAC6 inhibition downregulated pSTAT3 after
stimulation (Figure 23B-C). Ruxolitinib, a JAK2 inhibitor, was utilized as a positive control. Based
on these results, we predict a model where regulation of STAT3 signaling by HDAC6 can counter
the immunoregulatory phenotype of CLL B cells through reduction of PD-L1 and IL-10. In turn,
CLL T-cell phenotype is generally less suppressive and less exhausted due to less regulatory
signals from the CLL B cells (Figure 24). The CLL T cells can then carry out effector functions to
support antitumor activity.
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Figure 23. STAT3 signaling in murine B cells (A) IL-10 secretion from wildtype, euTCL1 or
euTCL1/HDAC6KO B cells was measured after ex vivo lipopolysaccharide stimulation for 24
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cytometry for intracellular proteins. Cells were isolated from splenocytes, fixed permed and
stained with antibodies for 1 hour at 4 degrees. Data is expressed as average and *p<0.05,
**p<0.005, ***p<0.0005.
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Figure 24. Proposed model for immunomodulatory effects of HDAC6 in CLL. We predict a
model where regulation of STAT3 signaling by HDAC6 can counter the immunoregulatory
phenotype of CLL B cells through reduction of PD-L1 and IL-10. In turn, CLL T-cell phenotype is
generally less suppressive and less exhausted due to less regulatory signals from the CLL B cells.
As a result, increased activation and cytolytic activity translate to antitumor effects.

Discussion
Based on this series of studies, we report for the first time that HDAC6 exhibits
immunomodulatory effects in CLL and can be combined with anti-PD1 antibody to augment
therapeutic effects. These effects occurred through increased activation and cytolytic activity of
CLL T cells. We propose a model where downregulation of STAT3 signaling by HDAC6
inhibition counters the immunoregulatory phenotype of the CLL B cells.
To date, HDAC inhibitors are clinically utilized for various diseases, including cancers.
Besides epigenetic regulation of gene expression, HDACs may regulate targets that are nonhistone proteins. In some cases, these properties relate to HDAC regulation of immune signaling
and therefore, immune function103. The ability of HDACs to regulate the immune system suggest
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promising potential therapeutic strategies, however, therapeutic potential for combination of
HDAC inhibition with immunotherapies has not been fully explored.
HDAC6 is a class IIb member with both histone and non-histone targets. Previously, it was
shown that HDAC6 physically interacts with STAT3 protein in antigen presenting cells77. This
study showed that HDAC6 inhibition led to decrease of STAT3 phosphorylation, decreased
recruitment of STAT3 to the IL-10 promoter, and abrogation of IL-10 production. Communication
between antigen presenting cells and T cells is critical for T-cell responses. During this process,
T cells activate, expand and are primed to exert cytolytic effects. Normal B cells can present
antigens to T cells, although they are not professional antigen presenting cells. However, CLL B
cells exhibit an immunosuppressive phenotype and immune synapse with T cells is defective.
This phenotype serves to avoid tumor immune surveillance and ultimately, escape clearance from
cytotoxic T cells.
Immune cells tend to harbor homogenous or related signaling pathways due to their
common lineage. Similar to antigen presenting cells, B cells also utilize STAT3 signaling. STAT3
signaling can be initiated via several surface receptors, including the B-cell receptor, IL-6 receptor,
and IL-10 receptor102, 104. CLL B cells are known for active STAT3 signaling, although the reason
for this activity is not clear. It may be a combination of several reasons, including tonic BCR
signaling, and increased concentrations of IL-6 and IL-10 in the CLL microenvironment.
Interestingly, a recent study demonstrated that ibrutinib treatment downregulated STAT3
signaling, and consequently, PD-L1 expression on CLL B cells and PD-1 expression on CLL T
cells11. This effect was cited as a reason why ibrutinib exerts immunomodulatory effects. In this
study, we focused on whether HDAC6 could downregulate STAT3 activation in the context of IgM
(BCR) stimulation or IL-6 (IL-6R) stimulation. In both cases, activation was downregulated. We
predict this may be due to the physical interaction of HDAC6 with STAT3 notwithstanding which
receptor initiated signaling.
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In this study, we did not explore whether HDAC6 inhibition in T cells directly inhibited
STAT3 signaling. It is possible that HDAC6 could directly impact STAT3 signaling in T cells.
Downregulation of multiple immune checkpoints on T cells and reduction of Tregs in vivo
suggested non-specific reversal of CLL T cell dysfunction, prompting us to focus on CLL B cells.
Further, our data from ex vivo mixed lymphocyte reactions implied that direct HDAC6 inhibition of
CLL B cells robustly countered suppression of T-cell activation. It must be acknowledged that the
mechanisms investigated here may not be the only mechanism of immune suppression that is
affected by HDAC6 inhibition, as CLL B cells employ multiple immunoregulatory strategies. In the
future, it will be interesting to continue to explore how HDAC6 interacts with signaling impacting
other immunoregulatory strategies in CLL B cells, T cells and other supportive immune fractions.
In conclusion, this data provides rationale that HDAC6 inhibition should be tested in
combination with anti-PD1 or other immune checkpoint inhibitors in CLL patients. This could
provide benefit for the subset of patients who relapse or progress after prior therapy.

Materials and methods
Cell culture
Cells were cultured in RPMI supplemented with 10% fetal bovine serum, 5% penicillinstreptomycin, 5% non-essential amino acids and 1% Mycozap, incubated at 37°C with 5% CO2.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Paque
density gradient separation medium. Cell isolations were performed using magnetic separation
kits (StemCell Tech, Cambridge, MA) and viability assays were conducted using Cell Titer-Blue®
Cell Viability Assay (Promega, Madison, WI) according to manufacturers’ protocols.
Reverse transcriptase quantitative polymerase chain reaction
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). Complementary
DNA was synthesized from RNA using iScript Reverse Transcriptase (BioRad, Hercules, CA).
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Primers against human Tbet, GATA-3, FoxP3, Axin2, 18s (Qiagen, Venlo, Netherlands) were
used together with iScript Reaction Mix (BioRad, Hercules, CA).
euTCL1 mouse model
25 x 106 leukemic splenocytes from euTCL1 or euTCL1/HDAC6KO transgenic mice were
adoptively transferred via tail vein into wild type (6-8 weeks old) syngeneic C57BL/6 mice to
induce CLL disease. Leukemic euTCL1 mice were defined as >6 months of age and >70% B cells
out of total lymphocytes in peripheral blood by flow analysis. Disease induction was confirmed by
significantly elevated white blood cell count within 3 weeks of adoptive transfer.
Flow cytometry
Cells were stained with indicated antibodies for 1 hour at room temperature. For
intracellular proteins, cells were fixed and permed in 90% methanol prior to staining for 1 hour at
4 degrees Celcius. Antibodies utilized were against mouse or human CD19, B220, IgM, CD5, PDL1, CD3, CD4, CD8, CD25, CD127, CD44, PD-1, LAG-3, STAT3 (s727), STAT3 (y705).
Antibodies were obtained from BD Biosciences, Franklin Lakes, NJ). Anti-mouse or human
Th1/Th2 cytokine bead array kit was obtained from BD Biosciences, Franklin Lakes, NJ and
protocol was conducted according to manufacturer’s instructions. Assays were run on LSRII (BD
Biosciences, Franklin Lakes, NJ. or iQue Screener (Intellicyt, Albuquerque, NM) and analyzed
with FlowJo software (TreeStar Inc., Ashland, OR).
Inhibitors
ACY738 and ACY1215 was supplied by Acetylon Pharmaceuticals. All other inhibitors
were obtained commercially. ACY738 was administered orally in chow at 25mpk per day. AntiPD-1 antibody was administered intraperitoneally at 3mpk, 3 times per week, for 6 weeks total. It
was diluted in sterile phosphate buffered saline. For in vitro assays, inhibitors were dissolved in
DMSO and stored in -20 degrees until use.
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Statistical analysis
Statistical significance between data sets was determined by unpaired, 2-tailed, or
Student’s t test if data were normally distributed, or using a Mann-Whitney U unpaired test if the
data were not normally distributed. For groups of 3 or more, 1-way ANOVA followed by Tukey’s
multiple comparisons test was used if the data were normally distributed, or a Kruskal-Wallis test
was used if the data were not normally distributed. For correlation studies, linear regression was
performed on data sets. A p value < .05 was considered significant. All analyses were conducted
using GraphPad Prism software v7 or Microsoft Excel v16.
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NOTE TO THE READER

Portions of the following chapter have been previously published: Maharaj, K et al.
Emerging Role of BCR Inhibitors in Immunomodulation of Chronic Lymphocytic Leukemia. Blood
Advances 1, 1867-1875 (2017)12 and have been included here with the journal’s permission (see
Appendix A for copyright policy).
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CHAPTER FOUR:
EMERGING ROLE OF BCR INHIBITORS IN IMMUNOMODULATION OF CLL

Introduction
Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as
ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their
direct impacts on crucial survival pathways in malignant B cells. However, these therapies also
have effects on T cells in CLL by mediating toxicity and possibly controlling disease. By focusing
on the effects of BCR signaling inhibitors on the T-cell compartment, we may gain new insights
into the comprehensive biological outcomes of systemic treatment to 1) further understand
mechanisms of drug efficacy, 2) predict toxicity or adverse events, and 3) identify novel
combinatorial therapies as well as diseases where the drugs can be repurposed. Here, we review
the occurrence of T-cell abnormalities in CLL disease in preclinical models and patient samples,
finding that, as well as supporting B cells directly, CLL T cells orchestrate immune dysfunction
and immune-related serious adverse events. We then continue to address the effects of clinically
available small molecule BCR signaling inhibitors on the immune cells, especially T cells, in the
context of concomitant immune-mediated adverse events and implications for future treatment
strategies. Our review suggests potentially novel mechanisms of action related to BCR inhibitors,
providing a rationale to extend their use to other cancers and autoimmune disorders.

Background
Components of the BCR signaling pathway are attractive therapeutic targets in CLL and
other B-cell malignancies.5 Selective inhibitors of BTK and PI3Kδ (such as ibrutinib and idelalisib,
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respectively) have gained attention for significant clinical activity in CLL patients with relapsed or
refractory (R/R) disease.105 Because of pathway homology, BCR inhibitors also inhibit T-cell
signaling and activation to some degree.106 The effects of clinically available BCR inhibitors on T
cells need to be considered to fully understand mechanisms of efficacy and the occurrence of
adverse events. In this review, we will highlight the importance of T-cell biology in relation to CLL
development and discuss its possible role in treatment efficacy and the occurrence of adverse
events after current treatments.

T-cell abnormalities in CLL patients
Investigators have widely reported immune defects, including T-cell dysfunction, occurring
alongside CLL development in patients. Abnormal T cells act in collaboration with the CLL
microenvironment to support the growth of malignant B cells. In addition, T-cell abnormalities are
evidence of mechanisms of tumor immune-surveillance escape. Effects of T-cell changes on CLL
have emerged, including imbalance in T-cell subsets, exhausted phenotypes, dysregulation of coinhibitory molecules, increase in suppressive numbers and phenotypes, abnormal cytokine
secretion, and immune synapse and cytotoxicity defects.107 Below, we review studies that support
the possibility of targeting the tumor microenvironment (TME) by exploiting CLL T-cell defects.108

Imbalance of T-cell subsets
Overall changes in T-cell ratios have consistently been described in human CLL.109 One
such description is inverted CD4-to-CD8 ratio being attributed to the expansion of CD8+ T cells
in circulation, accompanied by Th2 preponderance and preferential expression of Th2-type
chemokine receptors on T cells.110, 111 CD4+ T cells accumulate in lymphoid tissue and associate
with CLL B cells to provide survival signals112 and to drive malignant progression. Interestingly, Tcell ratios may differ between niches in, for example, circulation versus lymphoid tissue.113
Evidence suggests that CD8+ expansion in CLL may be related to a CLL-specific adaptive
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immune response. Next-generation sequencing of CLL T cells have documented clonal
architecture and provided evidence that antigen drive could underlie expansion in a CLL-specific
context.114 Another theory postulated that chronic viral infection is a likely culprit for inducing Tcell changes in CLL patients.115 However, T-cell defects have not been shown to correlate with
cytomegalovirus-positive or cytomegalovirus-negative status in CLL patients. Subsequent studies
did not find functional impairment in cytomegalovirus-specific CD8+ T cells.116, 117 Further studies
on how cytomegalovirus-specific T cells in CLL maintain functionality may offer insight into
repairing dysfunctional CLL T cells.
Another description of T-cell imbalance is the observation that expansion of CD4+FoxP3+
regulatory T cells (Tregs) is characteristic of changes in T-cell ratios in CLL. These changes have
been correlated with progression and prognostic markers like IGVH mutation status and CD38
expression. Increases in CD8+CD25HIFOXP3+ cells have also been correlated with
progression.118 After fludarabine or thalidomide treatment, Treg decreases indicate a mutualistic
relation between Tregs and malignant B cells necessary for immune homeostasis in CLL.119, 120
Interestingly, Tregs are not the only suppressive population involved, as myeloid-derived
suppressor cells (MDSCs) are also implicated in CLL progression.16 Evidence indicated that low
T-helper 17 (Th17) numbers, interleukin (IL)-17+ cytotoxic T-cell numbers, and decreased IL-17
expression levels are correlated with poor prognoses.121 Induction of Th17 population with
lenalidomide implies a protective role for the Th17 subset against CLL progression.122 On the
other hand, induction of Th17 cells and associated cytokines may increase the possibility of
complications like autoimmune cytopenia. Accordingly, increased Th17 cells have been detected
in patients experiencing autoimmune cytopenia, with decreased Treg-to-Th17 ratio.123 The
mechanism responsible for this skewing has not been described, although it is suspected that IL10 secretion by malignant B cells may modulate Treg/Th17 differentiation.121, 122, 124
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Terminally differentiated and exhausted T cells
CLL patients have been shown to have decreased naive T cells and a shift toward the CD8+
effector memory phenotype.97, 125, 126 The accumulation of terminal memory in CLL may be due to
chronic antigen stimulation. Peptide-specific effector memory T cells recognizing the cytoskeletal
proteins vimentin and cofilin-1 have been detected in patient samples, establishing possible
autoantigens recognized by CLL B cells.127 In CLL patients, exhausted T cells classically exhibit
defective effector function, express inhibitory receptors, and proliferate poorly in response to
chronic infection.128 CLL T cells extensively upregulate exhaustion markers PD-1, CD244, CD160,
and intracellular CTLA-4, translating to defective proliferation and cytotoxicity.129, 130 Furthermore,
an increase of T-effector cells in CLL patients correlated with lowered PD-1 expression and better
prognoses.131 These data suggest a role for T-cell dysfunction as a therapeutic target to improve
tumor-induced immune suppression.

T-cell function
Differentially expressed genes in CD4+ CLL T cells occur in cell growth, differentiation,
proliferation, survival, cytoskeleton formation, and vesicle trafficking pathways.95 These changes
predict Th2 differentiation consistent with the data mentioned above. In CD8+ CLL T cells,
differentially expressed genes are involved in cytoskeleton formation, intracellular transport,
vesicle trafficking, and cytotoxicity. CLL B cells have been found to induce similar changes in
normal CD4+ and CD8+ T cells after ex vivo co-culture in a contact-dependent manner,
suggesting a reciprocal interaction.95
Subsequent functional analyses confirmed predicted defects.132 When CLL T cells form
impaired immune synapses with antigen-presenting cells (APCs), activation function is reduced.
It has been proposed that degranulation of cytotoxic T lymphocytes (CTLs) is a regulatory
mechanism of evasion utilized by malignant B cells to interfere with immune synapse formation.133
Further, abnormal cytoskeleton formation and vesicle packaging contributed toward defective
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cytotoxic response. Immunomodulation with lenalidomide improved immune synapse formation
between CLL T cells and B cells, validating the concept of targeting T-cell dysfunction in the CLL
TME.132 Cytokine profiles have also illustrated CLL-induced T-cell dysfunction. Increased IL-10
and IL-6 secretion by CLL B cells affords protection from CTLs,134 and increased IL-4 production
by circulating CD4+ T cells reiterates Th2 differentiation.113 IFN-γ and TNF-α secretion by CLL T
cells also provides extrinsic survival signals as part of the TME. When IL-21 and lenalidomide
treatment are combined, Bid-dependent CLL B-cell apoptosis was shown to be upregulated and
BCR signaling was inhibited.135
With improved understanding of the TME, novel targets continue to emerge. Recently, CD4+
CLL T cells were shown to internalize vesicles containing miR-363 secreted by CLL B cells and
silencing of miR-363 prevented T-cell alteration.136 Genome-wide analyses comparing CD8+ CLL
T cells to normal CD8+ T cells identified differentially methylated immune-regulatory genes,
including PD-1 promoter, KLRG1, and CCR6, confirming epigenetic reprogramming in CLL.111
We previously demonstrated that treatment of CTLs from CLL patients with hypomethylating
agent 5-aza-2-deoxycytidine caused a potentially beneficial Th1 polarization through
demethylation of Th1-specific promoters.15 In a later study, the epigenetic modifiers 5-aza-2deoxycytidine and LAQ824 effectively restored immunogenicity in CLL cell lines and primary CLL
patient cells.15 The combination treatment simultaneously improved T-cell activation and APC
function of CLL B cells. These works support the use of immunomodulating agents and dual
targeting to improve normative function of both T and B cells in CLL.

Lessons from preclinical CLL models
Preclinical

mouse

models

are

particularly

advantageous

for

investigating

CLL

immunobiology. Examining the CLL T-cell compartment has resulted in novel mechanisms for
CLL progression and interest in immunotherapeutic strategies.96, 100, 137 To study the dependence
of CLL B cells on immune subsets, carboxyfluorescein succinimidyl ester-labeled human CLL
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cells were injected into NSG mice alongside various immune components, such as CD34+
progenitor cells, mesenchymal stromal cells, or mature APCs.138 Data demonstrated that T cells
activated by allogeneic APCs were required for leukemic cell survival and proliferation.
Administration of anti-CD3 or anti-CD4 antibodies consistently reduced leukemic growth. Another
study proved that blockade of B-cell maturation is imposed by TME signals in CLL.139 These
findings relate to the efficacy of CLL therapies that function to 1) eliminate autologous T-cell
support for leukemic cells or 2) improve T-cell immune surveillance capacity to increase response
to CLL antigens.
Immunological studies in euTCL1 transgenic mice (which spontaneously develop CLL-like
CD5+ B-cell leukemia78) confirmed that leukemic B cells impaired T-cell function, which could be
reversed by lenalidomide treatment. Another study confirmed that a shift from naive to memory
T-cell phenotype in lymphoid tissue correlated with inverted CD4-to-CD8 ratio.137 In an
accelerated euTCL1 model, T-cell subset alterations induced by disease progression were found
to be antigen-driven and clonally skewed.137 McClanahan et al investigated CLL T-cell function in
aging and accelerated euTCL1 models in various niches.100 CD8+ T-cell proliferation was
increased in the spleen, in contrast to previous data reported from peripheral blood of late-stage
CLL patients. EuTCL1 B and T cells upregulated expression of PD-L1/PD-L2 and PD-1,
respectively, to control T-cell dysfunction. Other inhibitory receptors, KLRG-1, 2B4, and LAG-3,
also showed CLL-induced upregulation. Interestingly, PD-1+ euTCL1 T cells exhibited
heterogeneous functionality. Investigations of T-cell function in the spleen indicated that immune
synapse formation was increased at 6 months but impaired at 12 months, indicating
overcompensation during early-stage disease. Considering these data, the authors speculated
that T-cell exhaustion is not irreversible in CLL.100
Gassner et al also reported that euTCL1-derived T cells exhibited exhaustion.99 CD4+ T
cells upregulated PD-1 and LAG-3 expression in periphery and lymphoid tissues, and CD8+ T
cells upregulated LAG-3 expression. PD-L1 expression was modestly increased in CLL B cells
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from periphery tissue but was significantly increased in CLL cells from lymph nodes, implying a
TME effect. To investigate whether blocking the PD-1/PD-L1 axis in CLL has therapeutic potential,
euTCL1 mice were engrafted with a mixture of fluorescently labeled syngeneic leukemic cells,
some of which had been treated ex vivo with PD-L1 blocking antibody. These experiments implied
that PD-1/PD-L1 blockade could reactivate the CTL response within the euTCL1 transgenic
recipients to target malignant cells. Overall survival was not reported.99
Together, these exciting reports reiterate previously established trends in human CLL and
provide evidence that CLL T cells can be targeted with the intention of improving prognoses.98

Effect of BCR signaling inhibitors on T cells and other immune subsets and future
therapeutic implications
Although frontline therapy with chemo-immunotherapy is still appropriate for a subgroup of
younger CLL patients, it is often not well-tolerated in the older population.140, 141 Alternative drugs
ibrutinib and idelalisib have been developed to meet the needs of these patients. To date, ibrutinib
is approved as both a frontline and R/R CLL patient therapy, while idelalisib as well as duvelisib
is approved for R/R patients.142
Although consequences of the BCR signaling blockade are well-characterized in the
targeted malignant B cell, BCR inhibitors, including ibrutinib, idelalisib, and others, can interact
with multiple immune cell types, especially T cells. Dysfunctional T cells are related to the
occurrence of autoimmune hemolytic anemia complications in CLL patients. Recently, the control
of autoimmune hemolytic anemia with ibrutinib has been described in case reports, but available
data do not describe its incidence or outcomes in patients receiving idelalisib.143 Although how
these drugs interact with immune deficiency occurring in CLL is currently unknown, the complex
interaction of immune cells in this environment, as illustrated in Figure 25, makes the effects of
BCR inhibitors in immune subsets especially interesting.
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PI3K inhibitors and toxicity
PI3Kδ shows higher intrinsic activity in leukemic B cells compared to normal B cells and can
be therapeutically targeted in CLL. Idelalisib (targeting PI3Kδ) and duvelisib (also known as IPI145, targeting PI3Kγ/δ) have both demonstrated clinical responses attributed to their direct effects
on malignant B cells’ dependence on intrinsic and extrinsic survival signals.144, 145 Nevertheless,
their reported toxicities are a cause for concern. While data from early idelalisib CLL trials in R/R
patients reported only a 3% occurrence of serious adverse event (SAE) diarrhea, a subsequent
trial in previously untreated patients reported a 42.2% occurrence of diarrhea or colitis SAEs,
followed by high discontinuation rates. Other SAEs reported included hepatotoxicity and
pneumonitis.146, 147, 148 Grade 3/4 diarrhea and hepatotoxicity were reported in clinical trials with
duvelisib149 and the pan-PI3K inhibitor pilaralisib.150 These data indicate that this toxicity pattern
may be a class effect of PI3K inhibitors. In contrast, TGR-1202, a structurally different nextgeneration PI3Kδ inhibitor wirth CK1e activity, has been associated with substantially fewer
adverse events.151 However, despite TGR-1202 showing promising clinical efficacy in various Bcell malignancies, incidences of hepatotoxicity and colitis in comparison with previous PI3Kδ
inhibitors remain lower, even with long-term follow up.152, 153
T cells represent a secondary target cell population for PI3K inhibitors due to their
dependence on PI3Kδ and PI3Kγ isoforms for signaling. Early in vitro studies reported no
cytotoxic properties of idelalisib against normal CD3+ T cells but described a reduction of
inflammatory and anti-apoptotic cytokines.154 Recently, preliminary studies have reinvestigated
PI3K inhibitors in specific T-cell subsets to determine potential culprits with a role in autoimmune
toxicity. Matos et al reported that patients who received idelalisib showed decreased Treg number
and function. Tregs in patients experiencing autoimmune toxicities showed decreased expression
of the functional markers GITR, T-bet, CXCR3, granzyme-B, and TIM-3. Tregs also
downregulated pro-survival BCL-2 and increased pro-apoptotic CD95.155 Our group subsequently
described the differential effect of TGR-1202 in normal human T cells and murine CLL T cells
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compared with idelalisib and duvelisib.156, 157 Treg numbers and function were depleted by all 3
inhibitors but were maintained closer to normal levels after TGR-1202 treatment. These data are
of relevance to determining why this inhibitor causes fewer incidences of SAEs in patients.
Further, Deng et al recently reported a previously unknown off-target effect of TGR-1202. TGR1202 silenced c-myc translation in leukemia and lymphoma cells through inhibition of casein
kinase 1 epsilon (CK1ε).68 The impact of this inhibition on T cells is currently unknown.

PI3K inhibition in immune subsets
Class I PI3-kinases are composed of a regulatory (p85 or p55) and a catalytic (class IA p110
alpha, beta, delta, or class IB gamma) subunit. Upon recruitment of subunits to the membrane at
phosphorylated YXXM motifs, PI3K signaling is initiated, which acts downstream to control varied
cellular functions, such as growth, proliferation, and apoptosis. While alpha and beta subunits are
ubiquitously expressed, delta and gamma are mainly expressed by leukocytes.158 Currently,
relative expression of the 4 class I PI3K catalytic subunit isoforms in immune cell types has not
been comprehensively characterized.
Data previously reported from genetically silenced mouse models might be useful in
predicting the modulation of immune subsets by PI3K inhibitors. The PI3Kδ-inactive mouse model
showed normal thymic development and T-subset ratios, but T cells exhibited reduced CD44
expression, indicating a role for the δ subunit in the differentiation of effector and/or memory T
cells. PI3Kδ-inactive T cells exhibited diminished proliferation and IL-2 production poststimulation. PI3Kδ-inactive mice developed mild inflammatory bowel disease characterized by
intestinal leukocyte infiltration, which was thought to result from dysfunctional Tregs.159
Impairment of the T-cell-mediated immune response has been partly explained by the recent
discovery that PI3Kδ promotes CD4+ T-cell interactions with APCs by increasing LFA-1 binding
to ICAM-1.160 In addition, PI3Kδ-inactive Tregs produced less IL-10 and expressed lower levels
of CD38+, correlating to defective suppressive function.161 PI3Kδ-inactive Tregs were incapable
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of protecting against a model of induced colitis. RAG-knockout (KO)/PI3Kδ inactive mice receiving
CD4+ T cells developed severe colitis, showing increased percentages of IFN-γ- and IL-17Aproducing lamina propia CD4+ T cells compared with RAG-KO mice.162 Despite overall reduced
inflammatory T-cell response, PI3Kδ-inactive mice exhibited improved resistance to bacterial
infections, possibly due to reduced Treg expansion and tissue homing.163, 164
Investigations with PI3Kγ-inactive or PI3Kγ-KO mice have also highlighted roles for this
catalytic isoform in T-cell development, trafficking, activation, and Th1 and Th17 responses.
Unlike PI3Kδ, PI3Kγ has been linked to chemokine-receptor signaling through G-protein-coupled
receptors but not T-cell receptors (TCRs). The tumor-reactive CD8+ effector T-cell population is
of interest because of its involvement in anti-tumor immunity.165 Murine PI3Kγ-KO CD8+ effector
T cells displayed impaired migration following viral challenge,166 suggesting that PI3Kγ could
regulate tumor-reactive CD8+ effector T cells. PI3Kγ is also involved in the regulation of dendritic
cell (DC), neutrophil, and monocyte migration.167 Further, studies of PI3Kγ/δ double KO mice
showed dramatic reductions in T cells in peripheral blood, lymph nodes, and spleen alongside
symptoms of lymphopenia.168 Functionally, Tregs of γ-KO/δ-inactive mice were deficient in
suppressive assays and expressed low levels of GITR and FoxP3. It was noted that lymphopenia
is associated with autoimmunity; however, a secondary factor is necessary to induce autoimmune
disease, such as dysfunctional Tregs or local tissue inflammation.169
Although there is now evidence that peripheral Treg function is compromised after PI3Kδ or
γ/δ genetic inactivation, experiments utilizing PI3K inhibitors to interrogate Treg function in vitro
have reported variable results, likely due to the context of dosing and stimulation. Tregs derived
from normal human peripheral blood mononuclear cells were selectively spared by PI3Kα, PI3Kδ,
or MEK inhibitors when compared with CD4+ CD25- (Tcon) and CD8+ (Teff) subsets.170 Tregs
retained closer to normal levels of proliferation, activation, and suppressive capacity following
anti-CD3/CD28 stimulation in the presence of these inhibitors. Most interestingly, PI3Kδ and
PI3Kα protein expression levels were lower in Tregs than in Tcons. This is consistent with
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observations that PI3K signaling inhibition can differentially affect Tregs versus Tcon or Teff and
suggests that protein expression of the PI3K catalytic isoforms should be quantified and
compared among immune subsets. Thus far, the clinical application of PI3K inhibitors resembles
the PI3Kδ-inactive mouse model, since peripheral Treg numbers and functions are compromised
in patients following PI3K inhibitor treatments.
Abu-Eid et al showed that PI3K-Akt pathway inhibition decreased Treg infiltration of the TC1 tumor and enhanced the anti-tumor effects of tumor-specific vaccinations.171 In another study,
Ali et al found that both genetic and pharmacological inactivation of PI3Kδ in Tregs conferred
resistance to solid tumor growth (4T1, EL4, and LLC) in mice. Although PI3Kδ blockade
weakened the cytotoxic T-cell response, Treg-mediated immune suppression was overridden and
an anti-tumor effect was achieved. PI3Kδ may be more essential for Treg response than effector
T-cell response,172 and PI3Kδ blockade may reinvigorate adaptive anti-tumor responses, implying
additional mechanisms for PI3K inhibitor efficacy against hematological and solid malignancies.
Alongside Tregs, other immune subsets have been implicated in PI3K-mediated anti-tumor
immunity. It was found that PI3K inhibition could relieve immunosuppression to augment the use
of Toll-like receptor (TLR) agonist for improving anti-tumor immunity in combination with DC
vaccines.173 In a comprehensive analysis utilizing inhibitors of all class I PI3K catalytic isoforms,
class I PI3K inhibition in DCs suppressed IL-10 and TGF-β secretion. However, PI3K inhibition
did not hinder pro-inflammatory induction of IL-12 and IL-1B after TLR5 ligand (flagellin)
treatment. The combination of pathogen-derived flagellin with pan-PI3K inhibition suppressed
tumor growth in subcutaneous B16, CT26, and LLC solid tumor models, with and without DC
vaccines. Here, it was demonstrated that both DC and tumor-infiltrating-lymphocyte populations
were functionally modulated by PI3Ki treatment and that both were involved in the anti-tumor
response.
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Ibrutinib in T cells and other immune cells
Although ibrutinib is known for its clinical success as an irreversible BTK inhibitor, it is also
the first clinically available inhibitor of inducible T-cell kinase (ITK). ITK is expressed in T cells and
belongs to the Tec kinase family. It is a major player in TCR signaling, activating PLC-γ and
downstream NFAT, nuclear factor-κB, MAPK pathway, calcium mobilization, cytoskeleton
reorganization, and synapse formation and adhesion.174 Gomez-Rodriguez et al demonstrated
the importance of ITK in regulating Th17/Treg lineage differentiation.175 Considering the
immunomodulatory effects of ITK inhibition, it is possible for ibrutinib to be repurposed for use in
other contexts.
Dubovsky et al explored the effects of ibrutinib in T cells using healthy human T cells, CLL
patient T cells, Jurkat T cells, and mouse models.176 This study established that ibrutinib treatment
irreversibly inhibited ITK to decrease downstream activation in Th2 cells but not Th1 or CD8+ T
cells, due to compensation by redundant resting lymphocyte kinase. Ibrutinib-treated CLL T cells
exhibited Th1 skewing via T-bet upregulation and JunB downregulation. Systemic treatment
confirmed these effects in euTCL1 mice. These data imply that ibrutinib may function through a
2-pronged approach to target malignant B cells directly, while reinvigorating a beneficial
inflammatory T-cell response in CLL. Using mouse models of leishmaniasis, leukemia, and
listeriosis, this study highlighted the therapeutic potential of ibrutinib in other diseases involving
disproportionate polarization of Th2 immunity.
Other studies have explored the effects of ibrutinib on the CLL immune microenvironment.
Niemann et al reported decreased T-cell activation, proliferation, and PD-1 expression in CLL
patients following ibrutinib therapy.177 Consistent with prior findings in ITK knockout mice, the
authors demonstrated reduced proliferation of circulating Th17 cells in these patients and
inhibition of Th17 differentiation in ex vivo assays. Additionally, ibrutinib treatment disrupted CLLmacrophage interactions in bone marrow specimens. Yin et al described an increase in CLL
patient TCR diversity following 1 year of ibrutinib therapy.178 Using next-generation sequencing,
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this paper demonstrated that pre-therapy TCRβ clones decreased while the number of productive,
unique clones increased during treatment. TCR diversity was positively correlated with clinical
efficacy and lower infection rates. In CLL mouse models, Chen et al determined that ibrutinib
treatment deregulated B cell surface membrane CXCR4 expression and signaling, disrupted the
homing of B-CLL cells to lymphoid tissue, and ultimately contributed to improved survival via this
novel mechanism.179 The effect of ibrutinib on CLL T cell migration and homing, however, is yet
to be studied.
In a pioneering work, Barfi et al harnessed the immunomodulatory capacity of ibrutinib in
combination with an immune checkpoint blockade (anti-PD-L1 antibody) to treat hematological
malignancies without intrinsic sensitivity to ibrutinib and solid tumors without BTK expression.180
In ibrutinib-insensitive PD-L1+ A20 lymphoma established in mice, combining ibrutinib with antiPD-L1 synergistically delayed tumor growth and prolonged survival. Tumor-specific T cells were
detected in mice treated with the combination. This result was recapitulated in ibrutinib-insensitive
J558 myeloma and 4T1 (breast cancer) with appreciably fewer metastatic lesions. Similar results
were seen with CT26 (colon cancer) tumor growth, with detection of T cells specific to the CT26
tumor antigen. The cured mice displayed long-term memory to CT26 antigens. Ibrutinib may
therefore enhance response to T-cell therapies.
In a simultaneous study, Barfi et al explored the concept of repurposing ibrutinib by
combining intratumoral vaccine with ibrutinib treatment in a mouse model of subcutaneous
lymphoma.181 Intratumoral administration of CpG activated local natural killer cells, macrophages,
and DCs through TLR9 agonist activity, resulting in local tumor regression but not systemic antitumor response. Systemic administration of ibrutinib alone caused mild tumor growth delay at all
sites. In contrast, combining CpG and ibrutinib resulted in complete and permanent tumor
regression at all sites. This effect was found to be CD4+ and CD8+ T-cell dependent. Infused T
cells that had been pre-treated with the combination prevented the outgrowth of tumors in new
recipient mice.
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The full extent of the immunomodulatory properties of ibrutinib remains unclear. Although
natural killer T cells and mast cells also express ITK, their responses to ibrutinib treatment are
not yet known. Natarajan et al identified that ibrutinib treatment decreased expression of MHCII
and CD86 but increased expression of CD80 on DCs. Ibrutinib-treated DCs also promoted T-cell
proliferation and enhanced IL-17 cytokine production in co-culture via TLR4-modulated
activation.182 Additionally, in a report from Stiff et al on the effects of ibrutinib treatment on MDSCs,
which express BTK, ibrutinib inhibited BTK phosphorylation.183 Together with reduced cell
migration and inhibition of in vitro MDSC generation, ibrutinib treatment also reduced MDSCs in
spleen and EMT6 murine mammary tumors. Further, ibrutinib treatment reduced MDSCs in a
melanoma model in a BTK-dependent fashion. These data potentiate alternative modes of action
for ibrutinib in previously unexplored immune cell types.
Acalabrutinib is a more selective BTK inhibitor than ibrutinib, demonstrating on-par antitumor
efficacy in CLL, both in preclinical models and patient trials.25,
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Preliminary comparison of

patients treated with ibrutinib or acalabrutinib suggests that the immunomodulatory capacity of
acalabrutinib is differentiated from that of ibrutinib, likely due to less off-target effects on Tecfamily kinases, including ITK. Ibrutinib but not acalabrutinib increased absolute numbers of CD4+
and CD8+ T cells enriched for effector memory subsets over naïve and central memory subsets.
Acalabrutinib did not change Treg-to-CD4 ratio or activation-induced cell death. Both treatment
groups did however, exhibit reduced PD-1 and CTLA-4 expression in CD4+ and CD8+ T cells.
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Figure 25: The CLL microenvironment. Immune cells in the CLL microenvironment show typical
phenotypic changes that support survival of the malignant B cell including alterations to T-cell
subsets and MDSCs (numbered 1-15). BCR inhibitors target intrinsic survival signals of CLL B
cells but can also affect signaling in other immune cell types.
Conclusions
CLL T-cell dysregulation trends have been well described, showing that altered subset
ratios and gene expression and function are necessary for and supportive of malignant
progression. In addition to supporting malignant B cells directly, CLL T cells orchestrate immune
dysfunction and immune-related SAEs. Immunomodulatory agents, monoclonal antibodies, and
epigenetic modifiers targeting CLL T-cell dysfunction have yielded promising preclinical results.
Clinically administered BCR inhibitors also display immunomodulatory properties, affecting a wide
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range of immune cell categories. Emerging data describing the immunomodulatory capacity of
BCR inhibitors predicts feasible combination strategies for ibrutinib with other immunomodulatory
agents in CLL, such as lenalidomide or histone deacetylase inhibitors. In addition, the modulation
of T cells by ibrutinib or PI3K inhibitors could augment anti-tumor responses from checkpoint
blockade in CLL, such as with anti-PD-L1 antibody. Our review of the impact of BCR inhibitors on
T cells and other immune compartments suggests potentially novel mechanisms of action,
providing a rationale to extend their use to other cancers and autoimmune disorders.
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CHAPTER FIVE:
THE DUAL PI3KD/CK1e INHIBITOR UMBRALISIB HAS DIFFERENTIAL AND
BENEFICIAL IMMUNOMODULATORY EFFECTS ON CLL T CELLS

Introduction
The in-clinic PI3K inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have
demonstrated high rates of response and progression-free survival in clinical trials of B cell
malignancies such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse
events has led to frequent discontinuations, limiting the clinical development of these inhibitors.
By contrast, the dual PI3Kδ/casein kinase-1-epsilon (CK1ε) inhibitor umbralisib (TGR-1202) also
shows high rates of response in clinical trials but has an improved safety profile with fewer severe
adverse events. The toxicities typical of this class of PI3K inhibitors are largely thought to be
immune-mediated, but these are poorly characterized. Here we report the effects of idelalisib,
duvelisib and umbralisib on regulatory T cells (Tregs) on normal human T cells, T cells from CLL
patients and T cells in an EuTCL1 adoptive transfer mouse CLL model. Ex vivo studies revealed
differential effects of these PI3K inhibitors, where only umbralisib treatment sustained normal and
CLL associated FoxP3+ human Tregs. Further, while all three inhibitors exhibit anti-tumor efficacy
in the EuTCL1 CLL model, idelalisib or duvelisib-treated mice displayed immune-mediated
toxicities and impaired function and reduced numbers of Tregs, whereas Treg number and
function was preserved in umbralisib-treated CLL-bearing mice. Finally, studies using an inhibitor
that selectively impairs CK1ε suggests that the improved safety profiles of umbralisib are due to
its roles as a dual PI3Kδ/CK1ε inhibitor that preserves Treg numbers and functions.
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Background and rationale
In mammalian cells PI3K signaling occurs upon the binding of a regulatory subunit (p85
or p55) with a catalytic subunit (p110α, β, δ, or γ) and this leads to activation of AKT and other
downstream effectors that control cell growth, survival and metabolism.185 In cells of
hematopoietic origin, the expression of the p110 PI3Kδ catalytic subunit predominates and plays
essential roles in B-cell development, survival and function.186, 187 For example, in mature B cells,
PI3K signaling is initiated downstream of B-cell receptor (BCR) signaling, where it controls
activation and differentiation responses,186, 187 and mice lacking a catalytically active p110δ are
viable but have impaired B cell responses.188 Notably, p110δ-deficient mice also display impaired
T-cell functions, and develop an inflammatory bowel syndrome that has been attributed to
defective regulatory T cells (Tregs) and that is manifest as marked lymphocyte infiltrates into
intestinal tissues.188 Given of these observations, the role of PI3K signaling in T cell differentiation,
function and immune tolerance has also been studied.189 The p110γ catalytic subunit is also
known to play important roles in PI3K signaling downstream of G-protein–coupled receptors in T
cells and myeloid cells.190, 191 PI3K inhibitors targeting p110γ isoform have been investigated in
the context of cancers and autoimmunity. However, it is unclear how p110δ and p110γ subunits
interact to enable PI3K signaling in T cells, what specific functions they each control, and if they
can act in a compensatory manner in cells lacking or inhibited in one isoform.
Dependence on PI3K signaling is conserved in malignant B cells, including chronic
lymphocytic leukemia (CLL) B cells,185, 192 and this has led to the recent clinical development and
FDA approval of PI3K inhibitors for the treatment of B-cell malignancies.193 However, there is a
lack of robust data characterizing the effects of these inhibitors in secondary target cell
populations. Due to the importance of PI3K signaling in multiple immune cell types, PI3K inhibitors
targeting one or more catalytic isoforms can have unexpected immunomodulatory effects, which
may vary depending on each inhibitor’s selectivity, potency and off-target profile.

81

The immunomodulatory properties of PI3K inhibitors are significant in the context of
hematological malignancies and other cancers. For example, while the anti-tumor effects of the
PI3K inhibitors idelalisib and duvelisib are clear, the high incidence of immune-mediated severe
adverse events (AEs) in clinical trials among patients with B-cell malignancies, including colitis,
pneumonitis and hepatotoxicity, has caused high rates of discontinuation that have limited the
development of a potentially long-term beneficial treatment.194 In contrast, treatment with
umbralisib, a next-generation dual inhibitor of PI3Kδ and casein kinase 1-epsilon (CK1ε),195 has
shown an improved safety profile characterized by less-severe AEs, even with long-term followup.196 IC50 values of idelalisib, duvelisib, and umbralisib against p110 isoforms in a cell-free
enzymatic assay have been previously published.197
It has been postulated that T cells may modulate PI3K-inhibitor-related AEs. Increased
inflammatory cytokine levels and decreased Treg numbers have been associated with the
development of toxicities in patients on idelalisib,198 and younger treatment-naïve patients, who
likely have more robust immune systems, were at higher risk of developing toxicities. There is a
clear need to understand the effects of pharmacological PI3K inhibition in T cells and other
immune populations.
In the context of hematological malignancies, T cells may develop a phenotype supporting
malignant progression, differing substantially from that of healthy T cells. For example, CLL
patients often harbor low numbers of T cells that display markers of exhaustion, are less
proliferative, and have inverted Th1/Th2 and CD4/CD8 ratios, and can also have increased Treg
numbers.12 Here we characterized the immunomodulatory effects of clinically available PI3Kδ
inhibitors, and report marked and differential effects of these drugs on Tregs in the setting of CLL.
Importantly, these analyses revealed superior toxicity profiles of the dual PI3K/CK1ε inhibitor
umbralisib versus idelalisib and duvelisib, and that these are associated with improved function
and sustained numbers of Tregs, supporting the clinical utility of this agent in the treatment of CLL
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Results
Suppressive T-cell phenotypes are differentially modulated by PI3K inhibitors
To initially assess potential immunomodulatory effects of PI3K inhibitors, normal human T
cells were isolated from healthy donor PBMCs. Isolated total T cells were cultured with PI3K
inhibitors idelalisib, duvelisib, umbralisib or vehicle (DMSO) for 24 hours at various doses, and
viability was measured by CellTiter-Blue assay. Treatment with these inhibitors did not
compromise the survival of normal T cells at doses of 0.1 to 10 μM (Figure 26A); hence, this dose
range was selected for all in vitro experiments. To confirm if these agents were on target, the
phosphorylation of AKT (pAKT) was used as a readout of PI3K pathway inhibition in normal
human T cells. As predicted, reductions in the levels of pAKT were observed and were found to
be similar among all inhibitors (Figure 26B).
To assess potential effects on T-cell functions, cytokine secretion was measured from the
supernatant of total T cells incubated with the three PI3K inhibitors (Figure 26C-D). Overall, Th1
and Th2 cytokines were decreased following treatment with PI3K inhibitors, yet levels of IL-10
production were higher following umbralisib treatment compared to idelalisib or duvelisib
treatment (Figure 26D). Finally, the low levels of IL-4 and IL-6 that were produced by normal T
cells were comparably reduced by treatment with the three PI3K inhibitors.
The potential effects of these PI3K inhibitors on T-cell fate was assessed by examining
the expression of T-helper (Th) lineage transcription factors by quantitative RT-PCR.

The

expression of Tbet (Th1) was markedly and comparably suppressed by all three PI3K inhibitors,
whereas the expression of the Th2 determination factor GATA-3 was unaffected (Figure 26E and
data not shown). Idelalisib or duvelisib treatment also led to a profound (>25-fold) suppression of
FoxP3 (Treg) expression, whereas FoxP3 levels were more sustained in umbralisib-treated T
cells (Figure 26E). Thus, PI3K inhibitors impair T-helper cell differentiation, and idelalisib or
duvelisib treatment has more suppressive effects on FoxP3+ Tregs than treatment with umbralisib.
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Given these findings, the effects of these PI3K inhibitors on anti-CD3/anti-CD28 activation
of total T cells from normal or CLL donors were assessed. Although PI3K treatment with did not
affect total T cell count or the CD4 to CD8 ratio (Figure 27A), total Treg numbers were reduced in
a dose-dependent fashion following treatment with idelalisib or duvelisib (gating strategy shown
in Figure 28). In contrast, Treg numbers were more sustained in umbralisib-treated T cells (Figure
27A and Figure 29A).

Interestingly, the cell surface expression of the immunosuppressive

checkpoint molecules PD-1 and CTLA-4 on Tregs was sustained on umbralisib-treated samples
but was suppressed by idelalisib or duvelisib treatment (Figure 27B and Figure 29B). These
findings were confirmed in a cohort of 6 normal donor samples and 5 CLL patient samples, where
percentage of Tregs, and surface levels of PD-1 and CTLA-4 on Tregs, was relatively preserved
in umbralisib-treated normal or CLL patient T cells (27C-F).
To assess the potential effects of PI3K inhibitors on Treg function, we performed a Treg
suppression assay, where normal donor Tregs were pre-treated with inhibitors for 24 hours,
washed, and then co-cultured with autologous responder CD4+ T cells. Treatment with duvelisib
and idelalisib impaired the suppressive capacity of Tregs, whereas umbralisib-treated Tregs
retained their suppressive capacity (Figure 30A, B).
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Figure 26. PI3K inhibitors impair normal human T-cell survival and function. (A) CellTiterBlue assay of T-cell viability after 24 hr treatment with the indicated concentrations of PI3K
inhibitors. (B) Inhibition of PI3K signaling in CD3+ T cells was measured by assessing levels of
pS473-AKT after 24 hr of incubation with inhibitors followed by stimulation with anti-CD3/antiCD28. (C-D) Cytokine bead array analysis of Th1/Th2 cytokines secreted from CD3+ T cells
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(24 hr). (E) The expression of Th transcription factors was assessed by qRT-PCR in CD3+ T cells
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**p<0.005, ***p<0.0005.
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Figure 27. Normal and CLL Tregs are differentially impaired by PI3K inhibitors. (A) CD3+ T
cells from normal donor peripheral blood were cultured with the indicated concentrations of PI3K
inhibitors in dose titration in the presence of anti-CD3/anti-CD28 for 72 hr. (B) PD-1 and CTLA-4
expression in Tregs (C) T cells (n=6) were isolated from peripheral blood and cultured with the
indicated inhibitors (1μM, 72 hr) followed by immunophenotyping. (D) CD3+ T cells were isolated
from previously frozen CLL patient PBMCs (n=5) and cultured with PI3K inhibitors and antiCD3/anti-CD28 for 72 hr followed by immunophenotyping. (E) PD-1 and CTLA-4 expression (MFI)
on normal donor Tregs (n=6) treated with the indicated inhibitors (1μM, 24 hr). (F) PD-1 and
CTLA-4 expression (MFI) on Tregs from CLL patients (n=5) treated with the indicated inhibitors
(1μM, 24 hr). PD-1 and CTLA-4 MFI were normalized to FMO controls. Graphs display mean
values and error bars represent standard deviation. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 28. Gating strategy to identify Tregs in human or mouse samples. PBMCs were
stained with antibodies indicated for 1 hour at room temperature in the dark. Cells were fixed and
permed then intracellular proteins were stained with antibodies indicated for 1 hour at 4 degrees.
Cells were gated on single, viable lymphocytes. Accucheck beads were used to determine
absolute counts.
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Figure 29. Effect of PI3K inhibitors on Tregs (A) Flow cytometry to detect Treg population in
normal human T cells treated ex vivo with PI3K inhibitors at various concentrations. Treg is
identified as CD3+ CD4+ CD25HI CD127LO FoxP3+. (B) PD-1 and CTLA-4 expression on Treg
population. Median fluorescence intensity is displayed corresponding to each histogram.
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Figure 30. Treg suppressive capacity is only modestly impaired by umbralisib treatment.
(A) Naïve CD4+ T cells were isolated from normal donor peripheral blood and cultured in Tregpolarizing conditions for 5 days. Tregs were washed and pre-treated as indicated for 24 hours,
and were then co-cultured with autologous, cell trace violet-labeled, responder T cells. Cell trace
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Histograms depicting division of responder T cells measured by flow cytometry from 1
representative donor. Graph shows quantification of suppression assay (n=3). Graphs display
mean values and error bars represent standard deviation. Data are representative of 3
independent experiments. *p<0.05, **p<0.005, ***p<0.0005.
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Differential effects of PI3K inhibitor treatment on CLL Tregs
To assess if differential regulation of Tregs by PI3K inhibitors was also manifest in the
setting of CLL, we utilized the EuTCL1 adoptive transfer mouse model of CLL. As predicted, oral
administration of idelalisib, duvelisib or umbralisib led to marked reductions in pAKT in EuTCL1 T
cells (Figure 31A). Pharmacokinetic analyses established that all three inhibitors were detectable
in plasma at 1 hour post-dosing (Figure 31B) and remained detectable ≤ 16 hours (data not
shown). Following oral administration of idelalisib, duvelisib or umbralisib (21 days, once daily, at
100 mg/kg) CLL burden (CD19+ CD5+ B cells) in peripheral blood was significantly decreased
compared to control (Figure 31C). Reduction in tumor burden was confirmed in splenocytes (data
not shown). Total CD3+ T-cell numbers were also lower in inhibitor- versus vehicle-treated mice
(Figure 31D), yet the CD4/CD8 ratio remained unchanged (Figure 31E). Notably, total Treg
numbers were higher in the umbralisib than the idelalisib or duvelisib groups (Figure 31F). The
expression of several surface markers involved in Treg suppressive function (TGFB-1, GITR,
CD73)199 was also higher in the umbralisib-treated cohort compared to idelalisib- and duvelisibtreated mice, suggesting umbralisib-treated Tregs also retain functional capacity in the CLL
setting (31G). Finally, to assess functional capacity, the four cohorts of EuTCL1 mice were
sacrificed and splenic CD3+ T cells were activated ex vivo. Notably, IL-10 production was more
sustained in T cells isolated from umbralisib-treated EuTCL1 mice (Figure 31H).
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Figure 31. Treatment with PI3K inhibitors differentially impairs Tregs in EuTCL1 mice. (A)
In vivo activity of PI3K inhibitors was assessed by monitoring levels of pS473-AKT in splenic T
cells after treatment for 3 days (100 mg/kg, once daily, oral gavage) in wild type mice (n=4 per
group). (B) EuTCL1 CLL-bearing recipient mice were randomized and treated for 21 days with
the indicated inhibitors (100 mg/kg, once daily, n=5 mice per group). The plasma concentration
of each PI3K inhibitor was measured by HPLC after collection of peripheral blood 1 hr after oral
gavage. (C) Anti-tumor efficacy of inhibitors was determined by quantifying CLL B cells in
peripheral blood following 21 days of treatment (100 mg/kg, n=5 mice per group). (D) Total CD3+
T-cell count in peripheral blood in the animals treated in (C). (E) CD4/CD8 ratio in peripheral blood
in the animals treated in (C). (F) Treg count in peripheral blood of animals treated in (C). (G-H)
Total CD3+ splenic T cells from the mice treated in (C) were stimulated ex vivo for 24 hr with antiCD3/CD28. Expression of functional markers on surface of Tregs was then determined by flow
cytometry and IL-10 secretion was measured from supernatant by CBA. MFI of functional markers
were normalized to FMO controls. Graphs display mean and error bars represent standard
deviation. Data are representative of 3 independent in vivo experiments. *p<0.05, **p<0.005,
***p<0.0005.
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Treg number is associated with incidence of immune-mediated toxicities in CLL
B-cell cancer patients treated with idelalisib, duvelisib and umbralisib can suffer from
immune-mediated toxicities.197 To investigate this phenomenon, we collected tissues susceptible
to AEs from EuTCL1 mice treated with the PI3K inhibitors. In a blinded histological analysis, each
mouse was assigned a toxicity grade based on histological features of the small intestine, colon
and liver (Table 4 and Figure 32). Idelalisib- and duvelisib-treated EuTCL1 mice accrued the
greatest toxicity grades, while umbralisib-treated EuTCL1 mice displayed a much lower incidence
of AEs (Figure 33A). This result was reminiscent of available toxicity data derived from clinical
use of these inhibitors.196, 198
It has been postulated that deleterious effects on Tregs may be involved in the regulation
of immune-mediated toxicities characteristic of PI3K inhibitors.197 Given the differences in
peripheral Treg number and function following treatment of EuTCL1 mice with these three PI3K
inhibitors, a correlation analysis was performed to determine if Treg number was related to
incidence of toxicities. Interestingly, a reduced number of peripheral Tregs positively correlated
with overall toxicity grade in EuTCL1 treated mice (Figure 33B).
To assess the effects of these PI3K inhibitors on Treg suppressive capacity in vivo, a
MHC-mismatched graft (C57Bl/6 bone marrow donor)-versus-host (Balb/c recipient) disease
(GVHD) mouse model was used where functional Tregs are known to dampen the course of
GVHD.200 Following engraftment, recipient mice were treated orally with umbralisib, idelalisib or
vehicle, and were followed for their course of disease. Notably, GVHD was exacerbated in mice
treated with idelalisib, while mice treated with umbralisib did not show any difference from the
vehicle cohort (Figure 33C). Finally, umbralisib-treated mice had 2-fold greater numbers of Tregs
than idelalisib-treated mice (Figure 33D). Thus, umbralisib treatment does not compromise Treg
suppressive functions in vivo.
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Table 4. Criteria for histological analysis of immune-mediated toxicity
Organ Site

Criteria for immune-mediated toxicity

Liver

inflammatory foci, hepatocyte injury

Small intestine

immune infiltrate, shortened villi, denuded mucosa

Colon

immune infiltrate, shortened villi, denuded mucosa

Figure 32. Histology of immune-mediated toxicity in CLL murine model. Representative
histology findings in liver, small intestine and colon of EuTCL1 CLL-bearing recipient mice treated
as described in Figure 4. Circles and arrows depict sites showing signs of toxicity by alterations
in histology. All images were captured at 10x magnification.
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CK1ε inhibition protects Tregs from the detrimental effects of PI3K inhibitors
Umbralisib is the only PI3K inhibitor known to inhibit CK1ɛ.195 Anti-CK1ɛ activity has been
implicated in the inhibitor’s antitumor activity toward B-cell lymphomas due to downregulation of
c-MYC (MYC).195 CK1ε drives canonical Wnt signaling in mammalian cells,201 where it suppresses
the activity the β-catenin destruction complex and promotes β-catenin nuclear translocation and
the transcription of WNT/β-catenin target genes.202 Accordingly, CK1ε silencing suppresses the
expression and activity of β-catenin and its target genes.203 Notably, WNT signaling has been
implicated in the differentiation and function of T-cell subsets,204 yet roles of CK1ε in T-cell function
have not been investigated.
To assess if CK1ε inhibition by umbralisib contributes to sparing normal and CLL Treg
number and function, we utilized a newly developed and potent CK1ε-selective small-molecule
inhibitor coined SR-4471, which does not inhibit the closely related isoform CK1δ or the more
distantly related family member CK1α.205 SR-4471 treatment did not affect normal T-cell survival
at doses of 0.5μM and below (Figure 34A), but did lead to marked reductions in the expression
of the WNT effector gene Axin2. Levels of Axin2 transcripts in normal T cells were also
suppressed by umbralisib treatment, but not by treatment with idelalisib (Figure 34B), suggesting
that inhibition of CK1ε by umbralisib was necessary for suppression of Axin2 expression.
To test if CK1ε inhibition also affects Treg biology, a Treg suppression assay was
conducted using human Tregs pre-treated with vehicle, SR-4471, the three PI3K inhibitors, or
combinations of SR-4471 plus PI3K inhibitors. As expected, treatment with PI3K inhibitors
impaired the suppressive functions of Tregs, and the repressive effects of umbralisib on Tregs
were more modest than those of idelalisib or duvelisib (Figure 35A, B). Further, treatment with
SR-4471 did not impair the suppressive activity of Tregs (Figure 35A, B). Notably, dual treatment
with SR-4471 impaired the deleterious effects of PI3K inhibitors on the suppressive functions of
Tregs (Figure 35A-B).
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To test if these findings were also manifest in the context of CLL, we treated splenic
EuTCL1 T-cells with SR-4471, umbralisib, idelalisib or duvelisib and assessed effects on the
expression of β-catenin and TCF-1, which are easily detectable by flow cytometry. Treatment with
SR-4471 or umbralisib led to a dose-dependent suppression of β-catenin and TCF-1 levels,
indicating ablation of WNT signaling, whereas this was not evident in idelalisib or duvelisib treated
cells (Figure 36A). Further, treatment of splenic EuTCL1 CD4+ T cells under Treg-polarizing
conditions revealed that, surprisingly, treatment with SR-4471 alone was sufficient to provoke
significant increases in Treg numbers compared to control, and that SR-4471 treatment improved
Treg numbers when added in combination with PI3K inhibitors (Figure 36B-C). The expression of
functional Treg markers TGFβ-1, GITR and CD73 were also generally increased by the
combination versus single treatments (Figure 37). Collectively, these findings are consistent with
the notion that CK1ε inhibition by umbralisib impairs reductions in Treg number and function that
are provoked by the idelalisib or duvelisib PI3K inhibitors (Figure 38).
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Figure 34. Effects of SR-4471 on normal human T cells. (A) CellTiter-Blue assay showing
viability of normal human T cells after 24 hrs of culture with SR-4471. (B) Normal human T cells
were treated for 24 hrs with the indicated inhibitors and then lysed in trizol. Axin2 mRNA levels
were measured by qRT-PCR. Graph displays DDCT. Error bars denote technical triplicates of a
representative donor.

96

Normalized to Mode

A

Cell trace violet
100
75

**
**
*

*

*

50
25
0

no

Tr
e

g

co
nt
r
D ol
M
SR SO
um -44
b 7
um ra 1
br lisi
a b
id + S
el R
id alis
el
a ib
du + S
ve R
l
du isib
v
+
SR

% divided responder cells

B

Figure 35. Effects of SR-4471 on Treg suppressive capacity (A) Treg suppression assay was
performed as in Figure 3, following treatment with PI3K inhibitors (1 μM) +/- SR-4471 (500 nM).
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representative donor. (B) Graph showing quantification of Treg suppression assay (n=3). Graph
displays mean values and error bars represent standard deviation. Data are representative of 3
independent experiments. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 36. CK1ε Inhibition promotes CLL Treg survival (A) Effects of PI3K (1 μM) and CK1ε
inhibitors (500 nM) on protein levels of β-catenin and TCF-1 in isolated EuTCL1 T cells as
determined by flow cytometry (n=3). (B-C) EuTCL1 splenic CD4+ T cells from 6-month-old
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are representative of 3 independent experiments. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 38. Proposed model for action of CK1e in T cells in canonical Wnt signaling. We
propose a model where downregulation of canonical Wnt signaling by CK1e inhibition allows more
binding of FoxP3 to IL-2 promoter and thus encourages Treg differentiation and function.
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Discussion
PI3K signaling is dysregulated in many cancers, including solid tumors and lymphoid
malignancies. Activating mutations occur in multiple genes that direct PI3K signaling, including
PI3KCA, PTEN, AKT, and mTOR.206 Mutations also occur in downstream effectors of PI3K
signaling, including antiapoptosis BCL-family proteins.207,
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Furthermore, mutations and the

resulting pathway activation are associated with acquired resistance to therapeutic agents.209, 210
Based on these data, PI3K inhibitors were developed for clinical application. Interestingly, several
antitumor mechanisms of action have been described, including inhibition of pro-survival
signaling, disruption of microenvironment signals and enhanced anti-tumor immunity.197
Accordingly, there has been a drive to develop isoform-selective inhibitors to enhance selectivity
in targeted cell types and reduce toxicity. Here we assessed the immunomodulatory effects of
PI3K inhibitors idelalisib, duvelisib and umbralisib, which differ in their clinical safety profiles.197
Idelalisib is the pioneer PI3K inhibitor that was FDA-approved in 2014 for the treatment of
patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL), for small lymphocytic
leukemia (SLL) patients who had received at least two prior systemic therapies. It was also
approved relapsed CLL patients in combination with rituximab.211 Although high response rates
and increased overall survival were demonstrated in patients treated with idelalisib, severe AEs
were well documented,194 and frontline trials for CLL patients were halted due to their high
incidence. Notably, disruption of the immune system has been linked to these AEs.155 For
example, idelalisib treatment was reported to impair production of IL-6, IL-10 and TNF-α by
activated CD3+ T cells and IFN-γ levels in activated NK cells.154 However, in vitro studies of
idelalisib did not characterize effects on CLL T cells and, considering the differences manifest in
T-cell subsets and function in CLL12, we reasoned that the immunomodulatory effects of PI3K
inhibitors could be more profound in this context. While our data agree with prior studies showing
no cytotoxicity of idelalisib against normal human T cells and a general reduction of Th1/Th2
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cytokine secretion, the data clearly indicate profound reductions in Treg number and function in
both normal and CLL human T cells following in vitro treatment.
Clinical data indicate a correlation between inhibition of p110δ and autoimmune
toxicities,155,
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and a decreased percentage of Tregs has been was associated with the

development of toxicities in patients treated with idelalisib.198 To thoroughly address the
immunomodulatory effects of the currently clinically available PI3Kδ inhibitors we directly
compared the effects of several PI3K inhibitors in a validated mouse model of CLL. Interestingly,
peripheral Treg number negatively correlates with incidence of autoimmune toxicity, suggesting
that functional Tregs are indispensable to protect against autoimmune toxicity. Thus, peripheral
Treg count and/or IL-10 secretion from peripheral blood T cells could be explored as potential
predictive biomarkers for autoimmune toxicities in patients that are treated with idelalisib or other
PI3K inhibitors.
Duvelisib is an inhibitor of both p110δ and p110γ.212 It is, however, more potent against
p110δ than idelalisib in cell-free enzymatic assays.196 Duvelisib has been tested as a
monotherapy and in combination with other agents to treat B-cell malignancies, and was recently
approved for R/R CLL patients in 2018. Its toxicity profile was similar to idelalisib and included
transaminitis, neutropenia, colitis and pneumonitis.197 Further, in vitro studies have demonstrated
cytotoxicity of duvelisib toward human CLL T cells and reductions in IL-2, TNF-α and IFN-γ
production from normal healthy human T cells.145 Concordant with these findings, duvelisib
treatment of normal and CLL T cells provokes reductions in Th1/Th2 cytokines, and in Treg
number and function. Further, despite duvelisib plasma levels being lower than idelalisib and
umbralisib in the EuTCL1 CLL model, the reductions in p-AKT in T cells were similar, the
decreases in Treg numbers were more profound and there was a higher incidence of toxicity
compared to vehicle or umbralisib-treated mice.
Umbralisib has enhanced selectivity for inhibiting p110δ over other PI3K isoforms and is
unique in that it also inhibits CK1ε.195 Umbralisib has been tested in clinical trials encompassing
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several B-cell malignancies with high response rates and progression-free survival similar to
those previously demonstrated with idelalisib. Notably, however, umbralisib has an improved
safety profile, with fewer incidences of immune-mediated AEs and less discontinuations due to
toxicities.196 Concordant with these findings, in the EuTCL1 model, umbralisib-treated mice
experienced the lowest level of immune-mediated toxicity among the three treatments, and this
was associated with higher numbers of functional Tregs. Although data from patients treated with
umbralisib that assesses lymphocyte subset number and distribution is not yet available, a
prediction from the findings presented herein is that the improved safety profile of umbralisib will
correlate with increased Tregs in treated patients.
Janovska and colleagues recently explored inhibition of CK1δ/CK1ε as a therapeutic
target in CLL.213 Interestingly, the noncanonical WNT receptor ROR1 is upregulated in the
malignant B-cells of CLL patients. CK1ε is essential for signaling downstream of ROR1, and
treatment with the dual CK1δ/CK1ε inhibitor PF-670462 elicited an anti-tumor benefit in the
EuTCL1 model.213 Since umbralisib is unique in its ability to selectively inhibit CK1ε, we reasoned
that this might account for the therapeutic and toxicity profile of this PI3K inhibitor. To our surprise,
treatment of EuTCL1 T cells with SR-4471, a newly developed and highly selective and potent
CK1ε inhibitor,205 led to increased numbers of Tregs, and improved Treg numbers when combined
with PI3K inhibitors. Further, the effects of SR-4471 were associated with suppression of βcatenin and TCF-1 in Tregs. Interestingly, others have recently shown that WNT pathway
stimulation in Tregs provokes TCF-1-dependent induction of IL2 transcription and the suppression
of FoxP3 transcriptional activity, resulting in decreased Treg function.214 Collectively, these
findings support a model whereby PI3Kδ inhibitors compromise Treg survival and function. This
effect can be disabled by inhibition of CK1ε, via a WNT-β-catenin pathway. The results suggest
that this circuit would be operational for a broad spectrum of malignancies treated with PI3K
inhibitors. They also suggest that once a CK1ε inhibitor safety candidate is developed that a CLL
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clinical trial testing its utility as a single agent or as combination therapeutic with PI3K inhibitors
should be considered.
Materials and methods
Cell culture
Cells were cultured in RPMI supplemented with 10% fetal bovine serum, 5% penicillinstreptomycin, 5% non-essential amino acids and 1% Mycozap, incubated at 37°C with 5% CO2.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Paque
density gradient separation medium. Cell isolations were performed using magnetic separation
kits (StemCell Tech, Cambridge, MA) and viability assays were conducted using Cell Titer-Blue®
Cell Viability Assay (Promega, Madison, WI) according to manufacturers’ protocols.
CLL patient samples
PBMCs were obtained from CLL patients. All participants gave written IRB-approved
informed consent for their blood to be used for research (#CR6_Pro00000316). Blood was
collected at the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). CLL patients
were diagnosed according to International Workshop on CLL 2018 guidelines.215 Patient
characteristics are detailed in Table 1 and patients were treatment-naïve at the time of sample
collection.
Treg polarization and suppression assay
Naïve CD4+ T cells were isolated from human whole blood using a Human CD4+ T cell
isolation kit and were cultured in Treg-polarizing conditions (50 IU/mL human IL-2, 5 ng/mL human
TGF-β1, Immunocult CD3/CD28 stimulation) for 5 days. Tregs were washed and treated with
inhibitors at 1 μM for 24 hr. Tregs were then cultured with autologous responder CD4+ T cells
labeled with CellTrace Violet (ThermoFisher Scientific, Waltham, MA) in a 1 to 5 (Treg:CD4+) ratio
for 5 days. CellTrace Violet dilution was measured via flow cytometry.
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PI3K and CK1ε Inhibitors
Idelalisib

(CAL-101)154

and

duvelisib

(IPI-145)212

were

obtained

commercially

(SelleckChem, Houston, TX). Umbralisib (TGR-1202)196 was kindly provided by TG Therapeutics.
The CK1ε-selective inhibitor SR-4471205 was synthesized by using appropriate modifications of a
published synthetic procedure for CK1d/ CK1ε inhibitors.216 Inhibitors were dissolved and stored
in DMSO at -20°C.
CLL mouse model
25 x 106 leukemic splenocytes from EuTCL196 mice were adoptively transferred via tail
vein into wild type (6-8 weeks old) syngeneic C57BL/6 mice to induce CLL disease. Leukemic
EuTCL1 mice were defined as >6 months of age and >70% B cells out of total lymphocytes in
peripheral blood by flow analysis. Disease induction was confirmed by significantly elevated white
blood cell count within 3 weeks of adoptive transfer. Inhibitors were administered as a suspension
in Tween-20 and 90% methylcellulose/deionized water once daily by oral gavage at indicated final
concentrations. At end point, animals were sacrificed for collection of organs. Peripheral blood
and spleen were used to assess tumor burden, immunophenotyping analysis and other in vitro
assays. Liver and gastrointestinal tract from tumor-bearing recipients were fixed in formaldehyde,
paraffin-embedded and H&E stained prior to histology analysis.
GVHD mouse model
5 x 106 bone marrow cells isolated from femurs of wild-type C57Bl/6 mice were adoptively
transferred into wild-type Balb/c mice that were previously irradiated with 900 rads. Treatment
was administered via oral gavage beginning one day post adoptive transfer. Incidence of GVHD
was tracked by weight loss over time.
Flow cytometry
Immunophenotyping analysis was performed via flow cytometry. All markers were gated
according to fluorescence minus one or isotype controls. Acquisition was performed on a LSRII
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Cytometer (BD Biosciences, Franklin Lakes, NJ) and analyzed with FlowJo software v10.1 (Tree
Star, Ashland, OR). For staining and antibodies, see Supplemental Methods.
Statistical analysis
Statistical significance between data sets was determined by unpaired, 2-tailed, or
Student’s t test if data were normally distributed, or using a Mann-Whitney U unpaired test if the
data were not normally distributed. For groups of 3 or more, 1-way ANOVA followed by Tukey’s
multiple comparisons test was used if the data were normally distributed, or a Kruskal-Wallis test
was used if the data were not normally distributed. For correlation studies, linear regression was
performed on data sets. A p value < .05 was considered significant. All analyses were conducted
using GraphPad Prism software v7.
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CHAPTER SIX:
CONCLUSIONS AND FUTURE PERSPECTIVES

Treatment of disease conditions in cancer patients has been a challenge for physicians
and scientists for a long time. Despite vast improvements over the past few decades, we are still
in the infancy of understanding the biology of cancer. Aside from the option of bone marrow
transplant, CLL is a manageable but currently incurable disease. Studies over the past several
decades have collectively pieced together a picture of the characteristic molecular signatures of
CLL B cells. Researchers have identified signaling pathways, receptors, ligands and lineage
differentiation markers that are crucial for survival and function of malignant B cells.
The B-cell receptor signaling pathway has emerged at the forefront as the major source
of intrinsic survival, anti-apoptosis and proliferation signals, providing numerous opportunities for
developing small-molecule kinase inhibitors. The recent FDA approvals of ibrutinib, idelalisib and
duvelisib have certainly changed the paradigm for treatment of CLL patients, promising greater
efficacy, long duration of responses, and more options for the niche of patients that are unfit,
elderly, or have relapsed from conventional therapy. More options are also available for younger
patients with high risk features. However, these inhibitors are in their early stages and far from
perfect. The preclinical development of more selective, less toxic, and overall better optimized
compounds has been ongoing.
Overall, this work has contributed knowledge of antitumor targets for CLL patients, and
has developed understanding of how antitumor targeting affects signaling pathways to modulate
efficacy and safety of inhibitors. The studies reported here describe the potential of an epigenetic
modifier, histone deacetylase 6, as a therapeutic target in CLL. Histone deacetylase 6 silencing
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or pharmacological inhibition was found to downregulate BCR signaling, causing less survival,
proliferation and anti-apoptosis signals for CLL B cells. Further, the concept was tested using a
selective HDAC6 inhibitor, ACY738, in a preclinical murine CLL model. The rational combination
of ACY738 plus ibrutinib reduced tumor burden and increased survival of mice with CLL
significantly longer that either single agent, suggesting that this combination should be tested in
clinical trial.
Immune dysfunction of CLL patients is well described. Specific CLL immune phenotypes
have been reported, especially characterizing T-cell subsets. However, the picture is vague at
best. With development of technology and increasing knowledge of immune biology, the
importance of CLL immune interactions, costimulatory and coinhibitory signals, and tumor
microenvironment is becoming clear. But, there is still a general lack of understanding of how the
immune components work in tandem to progress the disease. This is partly due to the fact that
technical challenges are plentiful. For example, the isolation and activation of CLL patient T cells
has proved very difficult given the “exhausted” phenotype they portray. Opportunities to conduct
functional studies for CLL patient T cells remain limited.
Experiments with other immune compartments, for example, cells of the myeloid lineage,
are also difficult given that the functional cells reside within specific physiological niches. When
removed from their niches, function may be compromised. Considering these challenges,
preclinical mouse models, such as the euTCL1 transgenic model, have been extremely useful in
the study of the CLL microenvironment. It has long been postulated that targeting of the CLL
immunomicroenvironment can disrupt malignant cell survival. Interestingly, BCR inhibitors have
recently been found to modulate other CLL immune subsets in ways that may be contributing to
their antitumor mechanisms of action. The studies reported here demonstrated that HDAC6
exhibited immunomodulatory activity and implies that these properties can harnessed to reverse
T-cell dysfunction in CLL.
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Our studies provided evidence that HDAC6 inhibition impaired mechanisms of B-cell
derived immunosuppression, ultimately improving T-cell numbers and function in euTCL1 mice.
HDAC6 silencing or pharmacological inhibition resulted in altered levels of immune checkpoints
and other surface molecules important for T-cell antigen presentation on the CLL B cells and on
the CLL T cells. Based on this, the rational combination of ACY738 augmented the antitumor
activity of clinically available immune checkpoint inhibitor anti-PD1. Although not tested here,
ACY738 may have the potential to also augment the activity of other immune checkpoint inhibitors
in preclinical development, such as anti-PD-L1 and LAG-3. Future studies to investigate these
possibilities will be of interest.
Concerning clinical development of therapeutic agents, it has always been important to
strike a delicate balance between efficacy and toxicity. The BCR inhibitors and other
immunomodulatory agents and immunotherapies are notorious for their efficacy, but also for
sometimes unpredicted toxicities. As such, translational studies are more necessary than ever to
manage toxicities that hamper the development of the effective inhibitors. The case of the PI3K
inhibitors is particularly interesting. The primary research base focused on characterizing the
effects of PI3K inhibitors in normal and malignant B cells. When unexpected autoimmune-like
toxicities occurred, the culprit was suspected to be another immune population that harbored
similar signaling pathways, like T cells. Prior literature has indicated that T-cell function is
susceptible to PI3K inhibition, however, how these effects related to clinical applications was
unknown.
The studies described here facilitated comparison of the incidence of autoimmune-like
side effects of clinically available PI3K inhibitors in a CLL mouse model. Specifically, these results
definitively elucidated the contribution of Tregs to the incidence of side effects. Finally, these
studies described alternative pathway modulation by an off-target, CK1e, responsible for the
differential and beneficial effects of next-generation inhibitor, umbralisib, on Tregs. This study
reinforces the idea that all inhibitors are not created equal and immunomodulatory differences
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perceived as small can have huge clinical repercussions. Although not performed here, this study
could be extended to investigate other T-cell subsets after PI3K inhibition. For example, stem-like
memory CD8 and Th17 cells are also heavily regulated by PI3K signaling and have been found
to impact autoimmune disease conditions in the literature. The impact of PI3K inhibitors on these
T-cell subsets and other immune compartments in the context of efficacy and toxicity in CLL
patients will be interesting topics for future study.
CAR T cells have been very popular subjects for research and development in cancer
therapeutics. FDA approval of CAR therapies tiagenlecleucel and axicabtagene ciloleucel for nonHodgkin lymphoma and diffuse large B-cell lymphoma prove that CAR T cells are useful for
treatment of B-cell malignancies. However, CAR T therapy has been tested but not yet approved
in CLL. Because the T cells of CLL patients are few and difficult to expand, there is a growing
interest in the use of immunomodulatory agents to alter the phenotype of patient-derived T cells
to make them more amenable to transduction, survive longer, and persist in vivo. Investigations
surrounding CLL T-cell biology and the immunomodulatory drugs have become immensely
important. BCR inhibitors are being tested for the purpose of altering CLL T-cells, however,
epigenetic modifiers have not yet been tested. Epigenetic manipulation of T cells using
immunomodulatory histone modifiers could be useful for CAR T therapy and possibly other
adoptive cell therapies. Thus, interest in the role of epigenetic modifiers in the biology of normal
and malignant immune function continues to grow.
Within the bigger picture, the findings presented here imply that during development of
HDAC inhibitors, BCR inhibitors and other novel immunomodulatory therapeutics, basic and
translational research elucidating impacts on tumor cells and various immune subsets is very
useful to maximize efficacy and mediate toxicity. This includes modulation of complex tumor
survival signaling, along with signaling that controls immune evasion tactics. For immune cells
that home to the tumor microenvironment and or circulate the periphery, this includes modulation
of signaling that may offer support to the malignant progression of the tumor cells; signaling that
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controls disease symptoms and toxicities; and signaling that controls a suppressive versus
inflammatory response. On the other hand, elucidation of biology at this level will also point to
plausible biomarkers for development of clinical assays to gauge what is occurring in real time
when a patient is treated with an immunotherapy.
Recognition of the need for a comprehensive picture about how tumor cells and immune
cells interact in underway in the scientific community. To address this emerging need, the
application of interdisciplinary, new technologies and methods to research clinical challenges will
be paramount. New technologies, such as high-throughput genomics, proteomics, metabolomics
and the use of bioinformatics analysis to predict immune pathway modulation, will be instrumental
to advance cancer immunology and no doubt advance our ability to fully understand and harness
the potentially life-saving antitumor effects of the human immune system.
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